<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transbound Emerg Dis</journal-id><journal-id journal-id-type="iso-abbrev">Transbound Emerg Dis</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1865-1682</journal-id><journal-id journal-id-type="publisher-id">TBED</journal-id><journal-title-group><journal-title>Transboundary and Emerging Diseases</journal-title></journal-title-group><issn pub-type="ppub">1865-1674</issn><issn pub-type="epub">1865-1682</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7405402</article-id><article-id pub-id-type="doi">10.1111/tbed.13734</article-id><article-id pub-id-type="publisher-id">TBED13734</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Hypothetical targets and plausible drugs of coronavirus infection caused by SARS&#x02010;CoV&#x02010;2</article-title><alt-title alt-title-type="left-running-head">ALMASI and MOHAMMADIPANAH</alt-title></title-group><contrib-group><contrib id="tbed13734-cr-0001" contrib-type="author"><name><surname>Almasi</surname><given-names>Faezeh</given-names></name><xref ref-type="aff" rid="tbed13734-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="tbed13734-cr-0002" contrib-type="author" corresp="yes"><name><surname>Mohammadipanah</surname><given-names>Fatemeh</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0286-5342</contrib-id><xref ref-type="aff" rid="tbed13734-aff-0001">
<sup>1</sup>
</xref><address><email>fmohammadipanah@ut.ac.ir</email></address></contrib></contrib-group><aff id="tbed13734-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Pharmaceutical Biotechnology Lab</named-content>
<named-content content-type="organisation-division">Department of Microbial Biotechnology</named-content>
<named-content content-type="organisation-division">School of Biology and Center of Excellence in Phylogeny of Living Organisms</named-content>
<named-content content-type="organisation-division">College of Science</named-content>
<institution>University of Tehran</institution>
<city>Tehran</city>
<country country="IR">Iran</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Fatemeh Mohammadipanah, Pharmaceutical Biotechnology Lab, Department of Microbial Biotechnology, School of Biology and Center of Excellence in Phylogeny of Living Organisms, College of Science, University of Tehran, Tehran, Iran.<break/>
Email: <email>fmohammadipanah@ut.ac.ir</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>8</month><year>2020</year></pub-date><elocation-id>10.1111/tbed.13734</elocation-id><history><date date-type="received"><day>22</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>09</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>09</day><month>7</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2020 Blackwell Verlag GmbH <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 Blackwell Verlag GmbH</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:TBED-9999-na.pdf"/><abstract id="tbed13734-abs-0001"><title>Abstract</title><p>The world is confronting a dire situation due to the recent pandemic of the novel coronavirus disease (SARS&#x02010;CoV&#x02010;2) with the mortality rate passed over 470,000. Attaining efficient drugs evolve in parallel to the understanding of the SARS&#x02010;CoV&#x02010;2 pathogenesis. The current drugs in the pipeline and some plausible drugs are overviewed in this paper. Although different types of anti&#x02010;viral targets are applicable for SARS&#x02010;CoV&#x02010;2 drug screenings, the more promising targets can be considered as 3C&#x02010;like main protease (3Cl protease) and RNA polymerase. The remdesivir could be considered the closest bifunctional drug to the provisional clinical administration for SARS&#x02010;CoV&#x02010;2. The known molecular targets of the SARS&#x02010;CoV&#x02010;2 include fourteen targets, while four molecules of angiotensin&#x02010;converting enzyme 2 (ACE2), cathepsin L, 3Cl protease and RNA&#x02010;dependent RNA polymerase (RdRp)&#x000a0;are suggested as more promising potential targets. Accordingly, dual&#x02010;acting drugs as an encouraging solution in drug discovery are suggested. Emphasizing the potential route of SARS&#x02010;CoV&#x02010;2 infection and virus entry&#x02010;related factors like integrins, cathepsin and ACE2 seems valuable. The potential molecular targets of each phase of the SARS&#x02010;CoV&#x02010;2 life cycle are discussed and highlighted in this paper. Much progress in understanding the SARS&#x02010;CoV&#x02010;2 and molecular details of its life cycle followed by the identification of new therapeutic targets are needed to lead us to an efficient approach in anti&#x02010;SARS&#x02010;CoV&#x02010;2 drug discovery.</p></abstract><kwd-group><kwd id="tbed13734-kwd-0001">anti&#x02010;virals</kwd><kwd id="tbed13734-kwd-0002">drug repurposing</kwd><kwd id="tbed13734-kwd-0003">molecular targets</kwd><kwd id="tbed13734-kwd-0004">novel coronavirus</kwd><kwd id="tbed13734-kwd-0005">proteases</kwd><kwd id="tbed13734-kwd-0006">SARS&#x02010;CoV&#x02010;2</kwd></kwd-group><counts><fig-count count="2"/><table-count count="4"/><page-count count="15"/><word-count count="31383"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.6 mode:remove_FC converted:05.08.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="tbed13734-cit-1001">
<string-name>
<surname>Almasi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mohammadipanah</surname>
<given-names>F</given-names>
</string-name>. <article-title>Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2</article-title>. <source xml:lang="en">Transbound Emerg Dis</source>. <year>2020</year>;<volume>00</volume>:<fpage>1</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1111/tbed.13734</pub-id>
</mixed-citation>
</p></notes></front><body id="tbed13734-body-0001"><sec id="tbed13734-sec-0001"><label>1</label><title>INTRODUCTION</title><sec id="tbed13734-sec-0002"><label>1.1</label><title>Life cycle of the Coronavirus</title><p>Coronaviruses (CoVs), a member of the <italic>Coronaviridae</italic> family, are spherical (approximate diameters of 60&#x02013;140&#x000a0;nm), enveloped, positive&#x02010;sense RNA viruses and include four genera of <italic>Alphacoronavirus</italic>, <italic>Betacoronavirus</italic>, <italic>Deltacoronavirus</italic> and <italic>Gammacoronavirus</italic> (Cascella, Rajnik, Cuomo, Dulebohn, &#x00026; Di Napoli, <xref rid="tbed13734-bib-0012" ref-type="ref">2020</xref>; Li, Luk, Lau, &#x00026; Woo,&#x000a0;<xref rid="tbed13734-bib-0044" ref-type="ref">2019</xref>).</p><p>The <italic>betacoronavirus</italic> genome including SARS&#x02010;CoV&#x02010;2 comprises of the 5&#x02032;&#x02010;untranslated region (5&#x02032;&#x02010;UTR), 3&#x02032;&#x02010;untranslated region (3&#x02032;&#x02010;UTR), open reading frame (ORF) 1a/b, structural proteins and additional proteins. Sixteen non&#x02010;structural proteins (nsp 1&#x02013;16) are generated by a proteolytic process (mediated by 3C&#x02010;like main protease [3Cl protease] and papain&#x02010;like proteinase [PL proteases]) from the large replicase polyproteins (pp) (pp1a and pp1ab) encoded by the ORF1a/b. Nsps progress the organization of the replication&#x02013;transcription complex and indirect escape from the host immune system (Chan et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0013" ref-type="ref">2020</xref>).</p><p>Structurally, the ~30,000 nucleotide viral genomes also express four basic structural proteins of nucleocapsid (N), membrane (M), envelope (E) and spike (S), encoding from the 3&#x02032; end of the viral genome (Figure&#x000a0;<xref rid="tbed13734-fig-0001" ref-type="fig">1</xref>). The spike is a ~150&#x000a0;kDa homotrimer glycoprotein conferring crown&#x02010;like shape on the outer surface. The attachment of SARS&#x02010;CoV&#x02010;2 via the interplay of its S protein with the receptor on the host cell and angiotensin&#x02010;converting enzyme is the primary stage in its life cycle which is followed by proteolytic cleavage of S protein into 2 subunits namely S1 and S2 and virus enters the cytosol (S1 mediates attachment and S2 mediates virus fusion). N protein is structurally bound to the genome of the virus and is necessary for viral RNA transcription and replication. The other critical structural protein is M protein that is involved in shaping the viral envelope. By binding to the other proteins, this protein helps to stabilize N proteins and promotes the ending of viral assembly. Finally, the E protein plays a role in the production and maturation of SARS&#x02010;CoV&#x02010;2.</p><fig fig-type="FIGURE" xml:lang="en" id="tbed13734-fig-0001" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>The schematic diagram (original in this paper) of the SARS&#x02010;CoV&#x02010;2 surface proteins</p></caption><graphic id="nlm-graphic-1" xlink:href="TBED-9999-na-g001"/></fig><p>After the viral entry, the second step is the expression of replicase proteins. Following replication and RNA synthesis (third step) and assembly (last step), virions are escaped from the cell by the aid of exocytosis (Figure&#x000a0;<xref rid="tbed13734-fig-0002" ref-type="fig">2</xref>) (Fehr &#x00026; Perlman,&#x000a0;<xref rid="tbed13734-bib-0026" ref-type="ref">2015</xref>).</p><fig fig-type="FIGURE" xml:lang="en" id="tbed13734-fig-0002" orientation="portrait" position="float"><label>FIGURE 2</label><caption><p>Cell cycle of SARS&#x02010;CoV&#x02010;2 in the host cells. The virus goes into the target cells via direct membrane fusion (a) or a clathrin&#x02010;mediated endosomal pathway (b). Binding of the surface unit of the S protein (S1) to angiotensin&#x02010;converting enzyme 2 (ACE2) facilitates the viral attachment. Viral fusion is primed by TMPRSS2, and the active spike protein of SARS&#x02010;CoV&#x02010;2 acquires an RGD motif (in itsS1 domain) known to bind integrins. The attachment to integrin may play an auxiliary role in ACE2 binding, like simplifying endocytosis by signalling through the integrin. RGD is not found in other coronaviruses. The viral RNA is unveiled by the effect of endosomal cathepsins at low pH. Following, the replicase gene of the viral genome is translated into large polyproteins which are cleaved by the proteases to yield 16 non&#x02010;structural proteins (nsps). In consequence of replication, transcription and translation, assembly of nucleocapsids with RNA and N proteins is occurred in the cytoplasm, followed by budding into golgi intermediate compartment. Then, the enveloped virus is exocytosed. Plausible drugs inhibiting each step of the cycle are indicated in light blue boxes</p></caption><graphic id="nlm-graphic-3" xlink:href="TBED-9999-na-g002"/></fig></sec></sec><sec id="tbed13734-sec-0003"><label>2</label><title>CURRENT PLAUSIBLE DRUGS OF SARS&#x02010;COV&#x02010;2</title><sec id="tbed13734-sec-0004"><label>2.1</label><title>Potential drug compounds</title><p>There are three lines of drug discovery approach to develop the novel drug for SARS&#x02010;CoV&#x02010;2. These three approaches lead to the potential treatment options including the drug repurposing, screening molecular databases using drug design tools and screening the compound libraries in anti&#x02010;viral assays. By the time demanded to randomly screen the natural or chemical compound libraries, the third option is not compatible with the rapid rate of SARS&#x02010;CoV&#x02010;2 transmission in the community. Therefore, drug repurposing and computational docking analysis are the two main current approaches to find potential agents for SARS&#x02010;CoV&#x02010;2 therapy.</p><p>The efficiency of seven anti&#x02010;viral drugs (ribavirin, nafamostat, nitazoxanide, penciclovir, chloroquine (CQ) remdesivir and favipiravir) on only a single clinical type of SARS&#x02010;CoV&#x02010;2 is so far evaluated in the wet laboratory. These drugs have previously exhibited an acceptable anti&#x02010;viral activity on various types of RNA viruses such as SARS&#x02010;CoV, MERS&#x02010;CoV and Ebola virus (EBOV) (Garc&#x000ed;a&#x02010;Serradilla, Risco, &#x00026; Pacheco,&#x000a0;<xref rid="tbed13734-bib-0029" ref-type="ref">2019</xref>). The investigated potential anti&#x02010;SARS&#x02010;CoV&#x02010;2 described in recent repurposing programmes is presented in Table&#x000a0;<xref rid="tbed13734-tbl-0001" ref-type="table">1</xref>. The cell culture investigations showed that the compounds chloroquine (CQ) and remdesivir (RDV) effectively inhibited the infection by SARS&#x02010;CoV&#x02010;2 with a high selectivity index at low enough micromolar concentration (Wang et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0087" ref-type="ref">2020</xref>).</p><table-wrap id="tbed13734-tbl-0001" xml:lang="en" content-type="TABLE" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Potential repurposing candidates with effectiveness on SARS&#x02010;CoV&#x02010;2</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Drug candidate</th><th align="left" valign="top" rowspan="1" colspan="1">Target</th><th align="left" valign="top" rowspan="1" colspan="1">Anti&#x02010;viral mechanism of action</th><th align="left" valign="top" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Remdesivir</td><td align="left" rowspan="1" colspan="1">RNA polymerase</td><td align="left" rowspan="1" colspan="1">An adenine analogue that participates into nascent viral RNA chains and causes in pre&#x02010;mature termination</td><td align="left" rowspan="1" colspan="1">Wang et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0087" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Baloxavir marboxil</td><td align="left" rowspan="1" colspan="1">RNA polymerase</td><td align="left" rowspan="1" colspan="1">Cap&#x02010;dependent endonuclease inhibitor</td><td align="left" rowspan="1" colspan="1">Harrison&#x000a0;(<xref rid="tbed13734-bib-0031" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Triazavirin</td><td align="left" rowspan="1" colspan="1">RNA polymerase</td><td align="left" rowspan="1" colspan="1">A guanosine nucleotide analogue that inhibits RNA synthesis</td><td align="left" rowspan="1" colspan="1">Loginova et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0049" ref-type="ref">2011</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Favipiravir (Avigan)</td><td align="left" rowspan="1" colspan="1">RNA polymerase</td><td align="left" rowspan="1" colspan="1">Inhibits RNA&#x02010;dependent RNA polymerase (RdRp)</td><td align="left" rowspan="1" colspan="1">Wang et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0087" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ribavirin</td><td align="left" rowspan="1" colspan="1">RNA polymerase</td><td align="left" rowspan="1" colspan="1">Inhibits viral RNA synthesis and mRNA capping</td><td align="left" rowspan="1" colspan="1">Khalili, Zhu, Mak, Yan, and Zhu&#x000a0;(<xref rid="tbed13734-bib-0035" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Penciclovir</td><td align="left" rowspan="1" colspan="1">RNA polymerase</td><td align="left" rowspan="1" colspan="1">Inhibits RNA&#x02010;dependent RNA polymerase (RdRp)</td><td align="left" rowspan="1" colspan="1">Wang et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0087" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Acyclovir fleximer analogue</td><td align="left" rowspan="1" colspan="1">RNA polymerase</td><td align="left" rowspan="1" colspan="1">Inhibits RNA&#x02010;dependent RNA polymerase (RdRp)</td><td align="left" rowspan="1" colspan="1">Li and De Clercq&#x000a0;(<xref rid="tbed13734-bib-0042" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Galidesivir</td><td align="left" rowspan="1" colspan="1">RNA polymerase</td><td align="left" rowspan="1" colspan="1">Inhibits viral RNA polymerase function by terminating non&#x02010;obligate RNA chain</td><td align="left" rowspan="1" colspan="1">Li and De Clercq&#x000a0;(<xref rid="tbed13734-bib-0042" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ritonavir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits 3CLpro</td><td align="left" rowspan="1" colspan="1">Stower&#x000a0;(<xref rid="tbed13734-bib-0075" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">ASC09F</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">A combination drug containing ASC09 (HIV protease inhibitor) + ritonavir/ Oseltamivir</td><td align="left" rowspan="1" colspan="1">Li and De Clercq&#x000a0;(<xref rid="tbed13734-bib-0042" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Camostat</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Serine protease inhibitor with activity against the host TMPRSS2 protease</td><td align="left" rowspan="1" colspan="1">Li and De Clercq&#x000a0;(<xref rid="tbed13734-bib-0042" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Danoprevir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">A potent HCV protease (NS3/4A) inhibitor</td><td align="left" rowspan="1" colspan="1">Shah, Modi, and Sagar&#x000a0;(<xref rid="tbed13734-bib-0069" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nelfinavir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Xu et al. (<xref rid="tbed13734-bib-0094" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Colistin</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Liu and Wang&#x000a0;(<xref rid="tbed13734-bib-0046" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Valrubicin</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Liu and Wang&#x000a0;(<xref rid="tbed13734-bib-0046" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Icatibant</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Liu and Wang&#x000a0;(<xref rid="tbed13734-bib-0046" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bepotastine</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Liu and Wang&#x000a0;(<xref rid="tbed13734-bib-0046" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Epirubicin</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Liu and Wang&#x000a0;(<xref rid="tbed13734-bib-0046" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Epoprostenol</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Liu and Wang&#x000a0;(<xref rid="tbed13734-bib-0046" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vapreotide</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Liu and Wang&#x000a0;(<xref rid="tbed13734-bib-0046" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rupintrivir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Liu and Wang&#x000a0;(<xref rid="tbed13734-bib-0046" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lopinavir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Stower&#x000a0;(<xref rid="tbed13734-bib-0075" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ebselen</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Jin et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0034" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cinanserin</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Zhang and Liu&#x000a0;(<xref rid="tbed13734-bib-0102" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Flavonoids</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Zhang and Liu&#x000a0;(<xref rid="tbed13734-bib-0102" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Beclabuvir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Talluri&#x000a0;(<xref rid="tbed13734-bib-0076" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Saquinavir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Talluri&#x000a0;(<xref rid="tbed13734-bib-0076" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003b1;&#x02010;ketoamide</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Zhang, Lin, et al. (<xref rid="tbed13734-bib-0101" ref-type="ref">2020</xref>))</td></tr><tr><td align="left" rowspan="1" colspan="1">Hesperidin</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Adem, Eyupoglu, Sarfraz, Rasul, and Ali&#x000a0;(<xref rid="tbed13734-bib-0004" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Angiotensin II human acetate</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Contini&#x000a0;(<xref rid="tbed13734-bib-0016" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">GHRP&#x02010;2</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Contini&#x000a0;(<xref rid="tbed13734-bib-0016" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Indinavir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Contini&#x000a0;(<xref rid="tbed13734-bib-0016" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cobicistat</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Contini&#x000a0;(<xref rid="tbed13734-bib-0016" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Atazanavir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits chymotrypsin&#x02010;like protease (3CLpro)</td><td align="left" rowspan="1" colspan="1">Contini&#x000a0;(<xref rid="tbed13734-bib-0016" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mycophenolic acid</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits papain&#x02010;like protease (PLpro)</td><td align="left" rowspan="1" colspan="1">Elfiky and Ibrahim&#x000a0;(<xref rid="tbed13734-bib-0025" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Grazoprevir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits papain&#x02010;like protease (PLpro)</td><td align="left" rowspan="1" colspan="1">Elfiky and Ibrahim&#x000a0;(<xref rid="tbed13734-bib-0025" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Formoterol</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits papain&#x02010;like protease (PLpro)</td><td align="left" rowspan="1" colspan="1">Arya, Das, Prashar, and Kumar&#x000a0;(<xref rid="tbed13734-bib-0008" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Telaprevir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits papain&#x02010;like protease (PLpro)</td><td align="left" rowspan="1" colspan="1">Elfiky and Ibrahim&#x000a0;(<xref rid="tbed13734-bib-0025" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarylheptanoids</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">Inhibits papain&#x02010;like protease (PLpro)</td><td align="left" rowspan="1" colspan="1">Zhang and Liu&#x000a0;(<xref rid="tbed13734-bib-0102" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Darunavir/cobicistat alone or with lopinavir/ritonavir</td><td align="left" rowspan="1" colspan="1">Protease</td><td align="left" rowspan="1" colspan="1">An HIV&#x02010;1 protease and cytochrome P450 (CYP)3A enzyme inhibitor</td><td align="left" rowspan="1" colspan="1">Zhai et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0099" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ikarugamycin</td><td align="left" rowspan="1" colspan="1">ACE2</td><td align="left" rowspan="1" colspan="1">ACE2 inhibitors that block the site of viral spike protein interaction</td><td align="left" rowspan="1" colspan="1">Yang, Li, Bai, and Hou&#x000a0;(<xref rid="tbed13734-bib-0096" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Molsidomine</td><td align="left" rowspan="1" colspan="1">ACE2</td><td align="left" rowspan="1" colspan="1">Decrease the expression of ACE2</td><td align="left" rowspan="1" colspan="1">Yang et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0096" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Eriodictyol</p>
</td><td align="left" rowspan="1" colspan="1">ACE2</td><td align="left" rowspan="1" colspan="1">Binding potency to viral S protein at its host receptor or to the S protein&#x02013;human ACE2 interface</td><td align="left" rowspan="1" colspan="1">Smith and Smith&#x000a0;(<xref rid="tbed13734-bib-0073" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nitrofurantoin</td><td align="left" rowspan="1" colspan="1">ACE2</td><td align="left" rowspan="1" colspan="1">Binding potency to viral S protein at its host receptor or to the S protein&#x02013;human ACE2 interface</td><td align="left" rowspan="1" colspan="1">Smith and Smith&#x000a0;(<xref rid="tbed13734-bib-0073" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<p>Cepharanthine</p>
</td><td align="left" rowspan="1" colspan="1">ACE2</td><td align="left" rowspan="1" colspan="1">Binding potency to viral S protein at its host receptor or to the S protein&#x02013;human ACE2 interface</td><td align="left" rowspan="1" colspan="1">Smith and Smith&#x000a0;(<xref rid="tbed13734-bib-0073" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Baricitinib</td><td align="left" rowspan="1" colspan="1">Kinase</td><td align="left" rowspan="1" colspan="1">Janus&#x02010;associated kinase (JAK) inhibitor which is an important regulator of clathrin&#x02010;mediated endocytosis.</td><td align="left" rowspan="1" colspan="1">Richardson et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0063" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ruxolitinib</td><td align="left" rowspan="1" colspan="1">Kinase</td><td align="left" rowspan="1" colspan="1">Janus&#x02010;associated kinase (JAK) inhibitor blocking ACE2&#x02010;mediated endocytosis</td><td align="left" rowspan="1" colspan="1">Stebbing et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0074" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nitazoxanide</td><td align="left" rowspan="1" colspan="1">
<p>Interferon</p>
<p>response</p>
</td><td align="left" rowspan="1" colspan="1">Induces the host innate immune response to produce interferons</td><td align="left" rowspan="1" colspan="1">Wang et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0087" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nafamostat</td><td align="left" rowspan="1" colspan="1">
<p>Spike</p>
<p>glycoprotein</p>
</td><td align="left" rowspan="1" colspan="1">Inhibits the membrane fusion</td><td align="left" rowspan="1" colspan="1">Wang et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0087" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Teicoplanin</td><td align="left" rowspan="1" colspan="1">Cathepsin L</td><td align="left" rowspan="1" colspan="1">Antibiotic inhibiting the low&#x02010;pH cleavage of the viral spike protein by cathepsin L in the late endosomes</td><td align="left" rowspan="1" colspan="1">Zhang, Ma, et al. (<xref rid="tbed13734-bib-0100" ref-type="ref">2020</xref>))</td></tr><tr><td align="left" rowspan="1" colspan="1">Ciclesonide</td><td align="left" rowspan="1" colspan="1">Endoribonuclease</td><td align="left" rowspan="1" colspan="1">A corticosteroid that inhibits replication via inhibition of viral nsp15</td><td align="left" rowspan="1" colspan="1">Matsuyama et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0052" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Camrelizumab</td><td align="left" rowspan="1" colspan="1">Programmed cell death 1 (PD&#x02010;1)</td><td align="left" rowspan="1" colspan="1">A humanized monoclonal antibody (mAb) targeting PD&#x02010;1</td><td align="left" rowspan="1" colspan="1">AminJafari and Ghasemi&#x000a0;(<xref rid="tbed13734-bib-0006" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Emtricitabine</td><td align="left" rowspan="1" colspan="1">Reverse transcriptase</td><td align="left" rowspan="1" colspan="1">Non&#x02010;nucleoside reverse transcriptase inhibitor</td><td align="left" rowspan="1" colspan="1">Harrison&#x000a0;(<xref rid="tbed13734-bib-0031" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tenofovir</td><td align="left" rowspan="1" colspan="1">Reverse transcriptase</td><td align="left" rowspan="1" colspan="1">Nucleotide reverse transcriptase inhibitor</td><td align="left" rowspan="1" colspan="1">Harrison&#x000a0;(<xref rid="tbed13734-bib-0031" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Azvudine</td><td align="left" rowspan="1" colspan="1">Reverse transcriptase</td><td align="left" rowspan="1" colspan="1">Experimental reverse transcriptase inhibitor drug against HIV&#x02010;1/AIDS</td><td align="left" rowspan="1" colspan="1">Harrison&#x000a0;(<xref rid="tbed13734-bib-0031" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Methylprednisolone</td><td align="left" rowspan="1" colspan="1">Nuclear receptors</td><td align="left" rowspan="1" colspan="1">Synthetic corticosteroid that binds to nuclear receptors to dampen proinflammatory cytokines</td><td align="left" rowspan="1" colspan="1">Harrison&#x000a0;(<xref rid="tbed13734-bib-0031" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">IFN alpha&#x02010;1b</td><td align="left" rowspan="1" colspan="1">Immunomodulation</td><td align="left" rowspan="1" colspan="1">Bind to cellular surfaces' receptors and initiate the JAK&#x02010;STAT signalling cascades</td><td align="left" rowspan="1" colspan="1">Harrison&#x000a0;(<xref rid="tbed13734-bib-0031" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon alfa&#x02010;2a</td><td align="left" rowspan="1" colspan="1">Immunomodulation</td><td align="left" rowspan="1" colspan="1">Interferon alfa&#x02010;2b is a recombinant cytokine with anti&#x02010;viral properties</td><td align="left" rowspan="1" colspan="1">Li and De Clercq&#x000a0;(<xref rid="tbed13734-bib-0042" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tocilizumab</td><td align="left" rowspan="1" colspan="1">IL&#x02010;6 receptor</td><td align="left" rowspan="1" colspan="1">Immunosuppressive anti&#x02010;IL&#x02010;6 receptor mAb</td><td align="left" rowspan="1" colspan="1">Harrison&#x000a0;(<xref rid="tbed13734-bib-0031" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Amantadine</td><td align="left" rowspan="1" colspan="1">Viroporin E</td><td align="left" rowspan="1" colspan="1">Inhibits the uncounting stage</td><td align="left" rowspan="1" colspan="1">Aranda Abreu et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0007" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Thalidomide</td><td align="left" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1">Regulating immunity, inhibiting the inflammatory cytokine surge</td><td align="left" rowspan="1" colspan="1">Dastan et&#x000a0;al.&#x000a0;(<xref rid="tbed13734-bib-0018" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Umifenovir (Arbidol)</td><td align="left" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1">Membrane fusion inhibitor targeting the viral entry</td><td align="left" rowspan="1" colspan="1">Li and De Clercq&#x000a0;(<xref rid="tbed13734-bib-0042" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Chloroquine/ hydroxychloroquine</td><td align="left" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1">
<p>1. Elevate the pH of acidic intracellular organelles, such as endosomes/lysosomes</p>
<p>2. Inhibit the entry through changing the glycosylation of ACE2 receptor and spike protein</p>
</td><td align="left" rowspan="1" colspan="1">Touret and de Lamballerie&#x000a0;(<xref rid="tbed13734-bib-0081" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fingolimod</td><td align="left" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1">Sphingosine&#x02010;1&#x02010;phosphate receptor regulator</td><td align="left" rowspan="1" colspan="1">Rosa and Santos&#x000a0;(<xref rid="tbed13734-bib-0064" ref-type="ref">2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dipyridamole</td><td align="left" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1">Adenosine deaminase and phosphodiesterase inhibitor</td><td align="left" rowspan="1" colspan="1">Aly&#x000a0;(<xref rid="tbed13734-bib-0005" ref-type="ref">2020</xref>)</td></tr></tbody></table><table-wrap-foot id="tbed13734-ntgp-0001"><fn id="tbed13734-note-0001"><p>Abbreviation: ND, not determined.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap></sec><sec id="tbed13734-sec-0005"><label>2.2</label><title>Potential drug candidates in clinical trials</title><p>Remdesivir (RDV, GS&#x02010;5734) is an adenosine analogue that has completed the clinical trial phase III for the purpose of viral infection control caused by the Ebola virus. The remdesivir is entered to the phase III clinical trials in Asian countries to assess the use of anti&#x02010;viral drug candidate for the potential treatment of SARS&#x02010;CoV&#x02010;2 by Gilead Sciences. All reported potential drug candidates in clinical trials and their status are presented in Table&#x000a0;<xref rid="tbed13734-tbl-0002" ref-type="table">2</xref>. Moreover, multiple parallel attempts are in progress to develop SARS&#x02010;CoV&#x02010;2 vaccine. At the time of writing the article, 128 vaccine candidates are in preclinical phases and 16 candidates are in clinical phases (Table&#x000a0;<xref rid="tbed13734-tbl-0003" ref-type="table">3</xref>).</p><table-wrap id="tbed13734-tbl-0002" xml:lang="en" content-type="TABLE" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>Potential drug candidates for SARS&#x02010;CoV&#x02010;2 in clinical trials and their status in June 2020 based on clinicaltrials.gov database</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">ClinicalTrials.gov Identifier</th><th align="left" valign="top" rowspan="1" colspan="1">Intervention</th><th align="left" valign="top" rowspan="1" colspan="1">Mechanism of action</th><th align="left" valign="top" rowspan="1" colspan="1">Status (Phase)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NCT04343092</td><td align="left" rowspan="1" colspan="1">Ivermectin (IVM)</td><td align="left" rowspan="1" colspan="1">Inhibiting the importin (IMP) &#x003b1;/&#x003b2; receptor</td><td align="left" rowspan="1" colspan="1">I</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04321096</td><td align="left" rowspan="1" colspan="1">Camostat Mesilate</td><td align="left" rowspan="1" colspan="1">Protease inhibition</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04324996</td><td align="left" rowspan="1" colspan="1">Biological: NK cells, IL15&#x02010;NK cells,NKG2D CAR&#x02010;NK cells,ACE2 CAR&#x02010;NK cells, &#x02026;</td><td align="left" rowspan="1" colspan="1">Secreting The super IL15 superagonist and GM&#x02010;CSF neutralizing single&#x02010;chain variable fragment (scFv)</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04276688</td><td align="left" rowspan="1" colspan="1">Lopinavir/ritonavir; Ribavirin; Interferon Beta&#x02010;1B</td><td align="left" rowspan="1" colspan="1">Inhibition of protease and viral mRNA synthesis</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04280588</td><td align="left" rowspan="1" colspan="1">Fingolimod</td><td align="left" rowspan="1" colspan="1">Modulation of Sphingosine 1&#x02010;phosphate receptor</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04273529</td><td align="left" rowspan="1" colspan="1">Thalidomide</td><td align="left" rowspan="1" colspan="1">Inhibition of Inflammatory cells and cytokines</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04288102</td><td align="left" rowspan="1" colspan="1">Biological: Mesenchymal stem cells</td><td align="left" rowspan="1" colspan="1">Possessing a comprehensive immunomodulatory function</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04317092</td><td align="left" rowspan="1" colspan="1">Tocilizumab</td><td align="left" rowspan="1" colspan="1">IL&#x02010;6&#x02010;mediated signalling inhibition</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04321993</td><td align="left" rowspan="1" colspan="1">Lopinavir/ritonavir; Hydroxychloroquine sulphate; Baricitinib (janus kinase inhibitor); Sarilumab (anti&#x02010;IL&#x02010;6 receptor)</td><td align="left" rowspan="1" colspan="1">Protease and janus kinase inhibition, anti&#x02010;IL&#x02010;6 receptor</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04313023</td><td align="left" rowspan="1" colspan="1">PUL&#x02010;042 Inhalation Solution</td><td align="left" rowspan="1" colspan="1">Reducing the severity of SARS&#x02010;CoV&#x02010;2</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04275245</td><td align="left" rowspan="1" colspan="1">Meplazumab</td><td align="left" rowspan="1" colspan="1">Host cell expressed CD147 antibody Inhibition of the S protein binding to the cell</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04279197</td><td align="left" rowspan="1" colspan="1">Acetylcysteine</td><td align="left" rowspan="1" colspan="1">Mucolytic agent</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04311177</td><td align="left" rowspan="1" colspan="1">Losartan</td><td align="left" rowspan="1" colspan="1">Angiotensin II receptor blocker</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04292899</td><td align="left" rowspan="1" colspan="1">Remdesivir</td><td align="left" rowspan="1" colspan="1">RNA polymerase inhibition</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04325633</td><td align="left" rowspan="1" colspan="1">Naproxen</td><td align="left" rowspan="1" colspan="1">Prostaglandin G/H synthase inhibition</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04304313</td><td align="left" rowspan="1" colspan="1">Sildenafil citrate</td><td align="left" rowspan="1" colspan="1">cGMP&#x02010;specific phosphodiesterase type 5 (PDE5) inhibition</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04320615</td><td align="left" rowspan="1" colspan="1">Tocilizumab (TCZ)</td><td align="left" rowspan="1" colspan="1">IL&#x02010;6&#x02010;mediated signalling inhibition</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04315896</td><td align="left" rowspan="1" colspan="1">Hydroxychloroquine</td><td align="left" rowspan="1" colspan="1">Accumulation and raising the pH of the vacuole</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04317040</td><td align="left" rowspan="1" colspan="1">CD24Fc</td><td align="left" rowspan="1" colspan="1">Regulation of immune responses</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04261270</td><td align="left" rowspan="1" colspan="1">ASC09F&#x000a0;+&#x000a0;Oseltamivir; Ritonavir&#x000a0;+&#x000a0;Oseltamivir; Oseltamivir</td><td align="left" rowspan="1" colspan="1">Protease inhibition; neuraminidase inhibition</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04321616</td><td align="left" rowspan="1" colspan="1">Hydroxychloroquine; Remdesivir</td><td align="left" rowspan="1" colspan="1">Accumulation and raising the pH of the vacuole; RNA polymerase inhibition</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04315298</td><td align="left" rowspan="1" colspan="1">Sarilumab</td><td align="left" rowspan="1" colspan="1">IL&#x02010;6&#x02010;mediated signalling inhibition</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04324021</td><td align="left" rowspan="1" colspan="1">Emapalumab</td><td align="left" rowspan="1" colspan="1">Neutralizing the interferon&#x02010;gamma</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04252274</td><td align="left" rowspan="1" colspan="1">Darunavir and cobicistat</td><td align="left" rowspan="1" colspan="1">Protease inhibition&#x02010; cytochrome P450 3A (CYP3A) isoforms inhibition</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04308317</td><td align="left" rowspan="1" colspan="1">Tetrandrine</td><td align="left" rowspan="1" colspan="1">Not described</td><td align="left" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04286503</td><td align="left" rowspan="1" colspan="1">Carrimycin</td><td align="left" rowspan="1" colspan="1">Macrolide antibiotic</td><td align="left" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04254874</td><td align="left" rowspan="1" colspan="1">Arbidol Hydrochloride combined with Interferon atomization</td><td align="left" rowspan="1" colspan="1">Dual&#x02010;acting direct anti&#x02010;viral/host&#x02010;targeting</td><td align="left" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04263402</td><td align="left" rowspan="1" colspan="1">Methylprednisolone</td><td align="left" rowspan="1" colspan="1">Corticosteroid</td><td align="left" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04252885</td><td align="left" rowspan="1" colspan="1">Umifenovir (Arbidol)</td><td align="left" rowspan="1" colspan="1">Dual&#x02010;acting direct anti&#x02010;viral/host&#x02010;targeting</td><td align="left" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04255017</td><td align="left" rowspan="1" colspan="1">Umifenovir (Arbidol); Oseltamivir; Lopinavir/ritonavir</td><td align="left" rowspan="1" colspan="1">Dual&#x02010;acting direct anti&#x02010;viral/host&#x02010;targeting Neuraminidase inhibition; protease inhibition</td><td align="left" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04291729</td><td align="left" rowspan="1" colspan="1">Drug: Ganovo (Danoprevir)&#x000a0;+&#x000a0;ritonavir&#x000a0;&#x000b1;&#x000a0;Interferon nebulization</td><td align="left" rowspan="1" colspan="1">Protease inhibition</td><td align="left" rowspan="1" colspan="1">IV</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><table-wrap id="tbed13734-tbl-0003" xml:lang="en" content-type="TABLE" orientation="portrait" position="float"><label>TABLE 3</label><caption><p>Vaccine candidates for SARS&#x02010;CoV&#x02010;2 in clinical trials and their current status in June 2020 based on clinicaltrials.gov, ISRCTN registry and Chinese clinical trial registry database</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Identifier</th><th align="left" valign="top" rowspan="1" colspan="1">Interventions</th><th align="left" valign="top" rowspan="1" colspan="1">Mechanism of action</th><th align="left" valign="top" rowspan="1" colspan="1">Status (Phase)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NCT04400838</td><td align="left" rowspan="1" colspan="1">ChAdOx1</td><td align="left" rowspan="1" colspan="1">Non&#x02010;replicating viral vector</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04379336</td><td align="left" rowspan="1" colspan="1">Bacille Calmette&#x02013;Gu&#x000e9;rin (BCG)</td><td align="left" rowspan="1" colspan="1">Enhancing non&#x02010;specific immune responses through Bacillus Calmette&#x02010;Gu&#x000e9;rin&#x000a0;vaccination</td><td align="left" rowspan="1" colspan="1">III</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04412538</td><td align="left" rowspan="1" colspan="1">Inactivated&#x000a0;SARS&#x02010;CoV&#x02010;2</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04276896</td><td align="left" rowspan="1" colspan="1">LV&#x02010;SMENP&#x02010;DC</td><td align="left" rowspan="1" colspan="1">Lentiviral vector system (NHP/TYF) expressing viral proteins and immune modulatory genes to modify dendritic cells (DCs) and to activate T cells</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04383574</td><td align="left" rowspan="1" colspan="1">Inactivated&#x000a0;SARS&#x02010;CoV&#x02010;2</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04436471</td><td align="left" rowspan="1" colspan="1">Adeno&#x02010;based</td><td align="left" rowspan="1" colspan="1">Non&#x02010;replicating viral vector</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">ChiCTR2000031781</td><td align="left" rowspan="1" colspan="1">Adenovirus Type 5 Vector</td><td align="left" rowspan="1" colspan="1">Non&#x02010;replicating viral vector</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">ChiCTR2000031809</td><td align="left" rowspan="1" colspan="1">Inactivated&#x000a0;SARS&#x02010;CoV&#x02010;2</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">I/II</td></tr><tr><td align="left" rowspan="1" colspan="1">ChiCTR2000032459</td><td align="left" rowspan="1" colspan="1">Inactivated&#x000a0;SARS&#x02010;CoV&#x02010;2</td><td align="left" rowspan="1" colspan="1">Inactivated</td><td align="left" rowspan="1" colspan="1">I/II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04368988</td><td align="left" rowspan="1" colspan="1">Recombinant Spike Protein</td><td align="left" rowspan="1" colspan="1">SARS&#x02010;CoV&#x02010;2&#x000a0;Recombinant Spike Protein Nanoparticle&#x000a0;vaccine&#x000a0;(SARS&#x02010;CoV&#x02010;2&#x000a0;rS) with or without MATRIX&#x02010;M&#x02122; Adjuvant</td><td align="left" rowspan="1" colspan="1">I/II</td></tr><tr><td align="left" rowspan="1" colspan="1">ISRCTN17072692</td><td align="left" rowspan="1" colspan="1">LNP&#x02010;nCoVsaRNA</td><td align="left" rowspan="1" colspan="1">Self&#x02010;amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS&#x02010;CoV&#x02010;2</td><td align="left" rowspan="1" colspan="1">I</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04368728</td><td align="left" rowspan="1" colspan="1">3 LNP&#x02010;mRNAs</td><td align="left" rowspan="1" colspan="1">Not mentioned</td><td align="left" rowspan="1" colspan="1">I</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04405076</td><td align="left" rowspan="1" colspan="1">mRNA&#x02010;1273</td><td align="left" rowspan="1" colspan="1">Novel lipid nanoparticle (LNP)&#x02010;encapsulated mRNA&#x02010;based vaccine that encodes for a full&#x02010;length, spike (S) protein</td><td align="left" rowspan="1" colspan="1">II</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04313127</td><td align="left" rowspan="1" colspan="1">Ad5&#x02010;nCoV</td><td align="left" rowspan="1" colspan="1">Adenovirus type 5 vector that expresses S protein</td><td align="left" rowspan="1" colspan="1">I</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04336410</td><td align="left" rowspan="1" colspan="1">NO&#x02010;4800</td><td align="left" rowspan="1" colspan="1">DNA plasmid encoding S protein delivered by electroporation</td><td align="left" rowspan="1" colspan="1">I</td></tr><tr><td align="left" rowspan="1" colspan="1">NCT04299724</td><td align="left" rowspan="1" colspan="1">Pathogen&#x02010;specific aAPC</td><td align="left" rowspan="1" colspan="1">APCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins</td><td align="left" rowspan="1" colspan="1">I</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap></sec></sec><sec id="tbed13734-sec-0006"><label>3</label><title>MOLECULAR TARGETS OF SARS&#x02010;COV&#x02010;2 DRUG DISCOVERY</title><sec id="tbed13734-sec-0007"><label>3.1</label><title>Host attachment and entry</title><sec id="tbed13734-sec-0008"><label>3.1.1</label><title>Modification of host cell serine protease</title><p>Despite the possibility of surface alteration of RNA viruses, blocking the cell surface viral receptor, thereby inhibiting the virus entry, can be a proper option in designing the approach of drug discovery. Binding of the viral spike (S) glycoproteins to cellular receptor ACE2 and priming the S protein by transmembrane serine protease 2 (TMPRSS2) are both the essential factors for cell entry of coronaviruses. TMPRSS2 mediates the entry by two distinct mechanisms. One mechanism is the cleavage and activation of the spike glycoproteins of coronaviruses (like HCoV&#x02010;229E and HCoV&#x02010;EMC) which facilitates the virus&#x02010;cell membrane entry. Conformational flexibility of S protein which is needed for fusion will be created by proteolytic cleavages (Bosch, van der Zee, de Haan, &#x00026; Rottier,&#x000a0;<xref rid="tbed13734-bib-0010" ref-type="ref">2003</xref>) catalysed by TMPRSS2 as the most relevant cellular proteases in this process. Another mechanism is the proteolytic cleavage of angiotensin&#x02010;converting enzyme 2 (ACE2) by TMPRSS2, which might activate the coronavirus spike glycoprotein. Proteolytic cleavages of S protein happen only after ACE2 cleavage results in SARS&#x02010;CoV&#x02010;2&#x02010;cell membrane fusion and cathepsin L&#x02010;independent cell entry. SARS&#x02010;CoV&#x02010;2 RNA is then released into the cytoplasm, and viral replication is efficiently processed (Table&#x000a0;<xref rid="tbed13734-tbl-0004" ref-type="table">4</xref>).</p><table-wrap id="tbed13734-tbl-0004" xml:lang="en" content-type="TABLE" orientation="portrait" position="float"><label>TABLE 4</label><caption><p>Principle molecular targets of SARS&#x02010;CoV&#x02010;2 for drug discovery or design</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Viral cycle</th><th align="left" valign="top" rowspan="1" colspan="1">Molecular targets</th><th align="left" valign="top" rowspan="1" colspan="1">Potential anti&#x02010;viral drugs</th></tr></thead><tbody><tr><td align="left" rowspan="5" colspan="1">Host attachment and entry</td><td align="left" rowspan="1" colspan="1">Host cell serine protease receptor</td><td align="left" rowspan="1" colspan="1">Eriodictyol, Cepharanthine, Ergoloid, Nitrofurantoin</td></tr><tr><td align="left" rowspan="1" colspan="1">Host tyrosine kinase receptor</td><td align="left" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">ACE2<xref ref-type="fn" rid="tbed13734-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">Integrins</td><td align="left" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">Spike protein<xref ref-type="fn" rid="tbed13734-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">EK1C4</td></tr><tr><td align="left" rowspan="1" colspan="1">Uncoating</td><td align="left" rowspan="1" colspan="1">Ion channel proteins</td><td align="left" rowspan="1" colspan="1">Amantadine</td></tr><tr><td align="left" rowspan="2" colspan="1">Replicase Protein Expression</td><td align="left" rowspan="1" colspan="1">Papain&#x02010;like proteinase (PLpro)</td><td align="left" rowspan="1" colspan="1">Mycophenolic acid, Grazoprevir, Formoterol, Telaprevir, Diarylheptanoids, etc</td></tr><tr><td align="left" rowspan="1" colspan="1">3C&#x02010;like main protease (3CLpro)<xref ref-type="fn" rid="tbed13734-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">Ritonavir, Nelfinavir, Lopinavir, Ebselen, Cinanserin, Ketoamide, Atazanavir,</td></tr><tr><td align="left" rowspan="4" colspan="1">Replication of&#x000a0;viral genome</td><td align="left" rowspan="1" colspan="1">RNA&#x02010;dependent RNA polymerase (RdRp)<xref ref-type="fn" rid="tbed13734-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">Remdesivir, Baloxavir marboxil, Triazavirin, Favipiravir (Avigan), Ribavirin, Penciclovir, Acyclovir fleximer analogue, Galidesivir</td></tr><tr><td align="left" rowspan="1" colspan="1">Helicase</td><td align="left" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">The peptidyl/prolyl isomerases (PPIases)</td><td align="left" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">Nucleoside analogues</td><td align="left" rowspan="1" colspan="1">Remdesivir, Favipiravir, ribavirin, 5&#x02010;fluorouracil</td></tr><tr><td align="left" rowspan="1" colspan="1">Viral protein assembly</td><td align="left" rowspan="1" colspan="1">Envelope protein (protein E)</td><td align="left" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" rowspan="1" colspan="1">Cell release of the virus</td><td align="left" rowspan="1" colspan="1">ORF7a</td><td align="left" rowspan="1" colspan="1">ND</td></tr></tbody></table><table-wrap-foot id="tbed13734-ntgp-0002"><fn id="tbed13734-note-0002"><p>Abbreviation: ND, not determined.</p></fn><fn id="tbed13734-note-0003"><label>*</label><p>Indicates the sofar principle targets.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap></sec><sec id="tbed13734-sec-0009"><label>3.1.2</label><title>Angiotensin&#x02010;converting enzyme 2 (ACE2)</title><p>A type I membrane zinc metalloprotease named angiotensin&#x02010;converting enzyme 2 (ACE2) is mainly expressed in arterial cells and lung alveolar epithelial cells. ACE2 hydrolyses the angiotensin I to produce angiotensin (1&#x02013;9) (Donoghue et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0024" ref-type="ref">2000</xref>). The enzyme is known for its implication as the virus receptor of SARS&#x02010;CoV (Kuba et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0037" ref-type="ref">2005</xref>) which was proved as the cellular receptor of SARS&#x02010;CoV&#x02010;2 by Zhou et al (Zhou et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0104" ref-type="ref">2020</xref>). Blocking the entrance of SARS&#x02010;CoV&#x02010;2 through the intervention of ACE2 seems to be a possible target for anti&#x02010;viral drug discovery.</p></sec><sec id="tbed13734-sec-0010"><label>3.1.3</label><title>Integrins</title><p>Recently, Sigrist et al suggested that SARS&#x02010;CoV&#x02010;2 may also bind to integrins on the host cells, through a conserved motif (RGD) containing Arg&#x02010;Gly&#x02010;Asp in receptor&#x02010;binding domain of S protein that is absent in other coronaviruses (Sigrist, Bridge, &#x00026; Le Mercier,&#x000a0;<xref rid="tbed13734-bib-0072" ref-type="ref">2020</xref>). The conformational changes due to ACE2 binding expose the RGD containing region. Different viruses like Ebola virus (Schornberg et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0067" ref-type="ref">2009</xref>), human papillomavirus (Yoon, Kim, Park, &#x00026; Cheong,&#x000a0;<xref rid="tbed13734-bib-0097" ref-type="ref">2001</xref>), HIV&#x02010;1 (Monini et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0054" ref-type="ref">2012</xref>) and EBV (Tugizov, Berline, &#x00026; Palefsky,&#x000a0;<xref rid="tbed13734-bib-0082" ref-type="ref">2003</xref>) use integrins for cell attachment or entry. Treatment of multiple sclerosis/Crohn's diseases using the natalizumab antibody (&#x003b1;4&#x003b2;1/&#x003b2;7 integrin inhibitor) and the treatment of acute coronary syndrome with the small molecule tirofiban (&#x003b1;IIb&#x003b2;3 blocker) are examples of approved drugs based on the integrin inhibition, highlighting the impact of integrin in treatment of various diseases (Ley, Rivera&#x02010;Nieves, Sandborn, &#x00026; Shattil,&#x000a0;<xref rid="tbed13734-bib-0041" ref-type="ref">2016</xref>). These studies confirm that the inhibition of integrin may prevent the occurrence of some coronaviruses in host cells and can be considered a prolific target for anti&#x02010;viral drug discovery.</p></sec><sec id="tbed13734-sec-0011"><label>3.1.4</label><title>Host tyrosine kinase receptor</title><p>The growth factor receptors of receptor tyrosine kinases (RTKs) are autophosphorylated after ligand binding being involved in mediating cell&#x02010;to&#x02010;cell communication and controlling a vast range of complicated biological processes like cell growth, motility and differentiation (Lemmon &#x00026; Schlessinger,&#x000a0;<xref rid="tbed13734-bib-0040" ref-type="ref">2010</xref>). The sequel of ligand binding is conformational changes of RTKs enabling its autophosphorylation and therefore activation of a wide variety of downstream cellular signalling pathways. RTKs also play a critical role in signalling pathways, such as the Ras/mitogen&#x02010;activated protein kinase (MAPK), PI3K/Akt and JAK/STAT pathways. The particular RTK blockers, known as AG879 and tyrphostin A9 (A9), are also reported as strong anti&#x02010;viral activity against the influenza A virus (Kumar, Liang, Parslow, &#x00026; Liang,&#x000a0;<xref rid="tbed13734-bib-0038" ref-type="ref">2011</xref>). It was shown that the approved blockers can impair the infection of major HCV variants in in vitro and in vivo models (Jilg &#x00026; Chung,&#x000a0;<xref rid="tbed13734-bib-0033" ref-type="ref">2012</xref>). The tyrosine kinase inhibitor such as genistein can also block the replication of arenavirus, herpes simplex virus type 1 (HSV&#x02010;1) and HIV&#x02010;1 (Vela, Bowick, Herzog, &#x00026; Aronson,&#x000a0;<xref rid="tbed13734-bib-0084" ref-type="ref">2008</xref>). Dong et al introduced an RTK inhibitor named (A9) as a competent blocker of transmissible gastroenteritis virus (TGEV) infection belong to <italic>Alphacoronavirus</italic> genera as a successor model for CoV in cell&#x02010;based assays (Dong et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0023" ref-type="ref">2020</xref>). The inhibitors of RTK suppress the viral replication through different mechanisms like interferon signalling, Raf/MEK/Erk pathway and the p38 signalling pathway. These achievements represent the RTKs as a probable host&#x02010;centred approach to treat the SARS&#x02010;CoV&#x02010;2.</p></sec><sec id="tbed13734-sec-0012"><label>3.1.5</label><title>Viral spike protein</title><p>The trimeric S glycoprotein responsible for the coronaviruses crown&#x02010;like appearance mediates attachment to the host receptor (Ou et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0056" ref-type="ref">2020</xref>). Despite the over 72% spike protein sequence similarity with SARS&#x02010;CoV, a peculiar furin&#x02010;like cleavage site at the S1/S2 position in the S protein sequence of the SARS&#x02010;CoV&#x02010;2 was identified, missing in the other SARS&#x02010;like CoVs (Coutard et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0017" ref-type="ref">2020</xref>). Following the host cell binding, cell penetration is facilitated by S protein priming using the cellular protease. Considering the S protein cleavage by furin&#x02010;like protease in the host cell, blocking S protein attachment or furin&#x02010;like cleavage sites are promising targets in drug discovery. Recently, Xia et al introduced a lipopeptide named EK1C4 that effectively block the SARS&#x02010;CoV&#x02010;2 infection in in vitro experiments with IC50 of 36.5&#x000a0;nM (Xia et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0093" ref-type="ref">2020</xref>) by blockage of membrane fusion mediated by S proteins. The presence of three vaccine candidates in clinical phases accentuates the importance of this protein in the process of drug development (Thanh et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0080" ref-type="ref">2020</xref>).</p></sec></sec><sec id="tbed13734-sec-0013"><label>3.2</label><title>Inhibition of genome uncoating</title><p>The cessation of the capsid disintegration by viral or host enzymes/proteins is a drug target explored against the influenza virus, rhinoviruses, hepatitis A, poliovirus and enteroviruses (Yamauchi &#x00026; Greber,&#x000a0;<xref rid="tbed13734-bib-0095" ref-type="ref">2016</xref>). In accordance with this approach, rimantadine inhibits the capsid disintegration by blocking the ion channel in the influenza virus (Balgi et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0009" ref-type="ref">2013</xref>). The herbal medicine of Japan called Maoto has also shown inhibitory activity on influenza virus A (PR8) presumed by inhibition of genome release (Masui et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0051" ref-type="ref">2017</xref>).</p><p>The only effort on blockage of uncoating step in the SARS&#x02010;CoV&#x02010;2 life cycle as a drug discovery target is reported by Aranda Abreu et al. They proposed an in situ models of amantadine as a drug to relieve the effects of SARS&#x02010;CoV&#x02010;2 by blocking the viroporin E (a proton channel) and inhibiting the viral uncoating (Aranda Abreu, Hern&#x000e1;ndez Aguilar, Herrera Covarrubias, &#x00026; Rojas Dur&#x000e1;n, <xref rid="tbed13734-bib-0007" ref-type="ref">2020</xref>). The S protein&#x02010;based vaccines can also induce antibodies that block the genome uncoating besides the blockage of viral receptor (Chen et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0014" ref-type="ref">2020</xref>). Furthermore, it is still not determined whether the uncoating of SARS&#x02010;CoV&#x02010;2 can occur in both acidic and neutral conditions similar to avian coronavirus (IBV) or its uncoating can be suppressed by the neutralization of the acidic condition of endosomes and its subsequent fusion.</p></sec><sec id="tbed13734-sec-0014"><label>3.3</label><title>Inhibition of replicase protein expression</title><p>Following the uncoating step, the replicase gene of the viral genome encodes two processed polyproteins (pp) named pp1a and pp1ab (Chan et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0013" ref-type="ref">2020</xref>). Then, viral proteinases perform post&#x02010;translational modification on the polyproteins yielding proteins that mediate the formation of viral replication complexes. The protease activities of all coronaviruses include both papain&#x02010;like proteinase (PLpro) and coronavirus 3C&#x02010;like protease which are encoded within the replicase polyproteins and mediate cleavage events. Due to their unrivalled and essential function in processing the viral polyprotein, these enzymes are appropriate targets for SARS&#x02010;CoV&#x02010;2 drug development.</p><sec id="tbed13734-sec-0015"><label>3.3.1</label><title>Protease</title><sec id="tbed13734-sec-0016"><title>Papain&#x02010;like proteinase (PLpro)</title><p>PLprotease or nsp3 releases proteins involved in both replication of coronavirus and infection processes. In addition to the LXGG motif found in&#x02010;between nsp1/2, nsp 2/3 and nsp 3/4, it has two other proteolytic activities, removal of ubiquitin (Ub) and ubiquitin&#x02010;like protein ISG15 (interferon induced gene 15) from cellular proteins. Some studies have highlighted the importance of inhibiting these proteases in other coronaviruses. Ratia et al introduced a compound, GRL0617, with an EC50 of 15&#x000a0;&#x003bc;M that inhibits the replication of SARS&#x02010;CoV in Vero E6 cells (Ratia et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0062" ref-type="ref">2008</xref>). PLpro inhibitors of MERS&#x02010;CoV (Kilianski, Mielech, Deng, &#x00026; Baker,&#x000a0;<xref rid="tbed13734-bib-0036" ref-type="ref">2013</xref>), HEV (Saraswat, Chaudhary, &#x00026; Sehgal,&#x000a0;<xref rid="tbed13734-bib-0065" ref-type="ref">2020</xref>), etc have also been reported. Another PLpro inhibitor named disulfiram has been identified to block the function of this enzyme in MERS and SARS in in vitro, but clinical approval of its effectiveness is lacking (Li &#x00026; De Clercq,&#x000a0;<xref rid="tbed13734-bib-0042" ref-type="ref">2020</xref>). The inhibition of PLpro can be assumed as a promising target in coronavirus drug discovery.</p></sec><sec id="tbed13734-sec-0017"><title>3C&#x02010;like main protease (3CLpro)</title><p>3CLprotease (also called the major protease (Mpro) or nsp5 directly mediates the polyprotein processing and maturation of viral non&#x02010;structural proteins (nsps), which is the indispensable part of the viral life cycle. Initiation of viral RNA synthesis and switching translation to RNA replication are other functions of this protein. 3CLpro is among the most attractive target for anti&#x02010;coronavirus drug development. Based on a recent computational drug repositioning research, five drugs, namely eravacycline, valrubicin, carfilzomib, lopinavir and elbasvir, have speculated to exhibit blocking activities on 3Cl pro of SARS&#x02010;CoV&#x02010;2 (Wang,&#x000a0;<xref rid="tbed13734-bib-0086" ref-type="ref">2020</xref>). According to another computational prediction, bortezomib, flurazepam, ponatinib, sorafenib and dasatinib are five other potent potential inhibitors of 3Cl pro for SARS&#x02010;CoV&#x02010;2 (Nguyen, Gao, Chen, Wang, &#x00026; Wei,&#x000a0;<xref rid="tbed13734-bib-0055" ref-type="ref">2020</xref>).</p><p>Due to the similar active&#x02010;site architecture of the 3Cl protease in coronaviruses and enteroviruses, Zhang et al designed peptidomimetic &#x003b1;&#x02010;ketoamides as proper 3Cl protease inhibitors to attain the broad&#x02010;spectrum anti&#x02010;viral drugs. They introduced a compound (11r) expecting to exhibit excellent anti&#x02010;viral activity against SARS&#x02010;CoV&#x02010;2 (Li &#x00026; De Clercq,&#x000a0;<xref rid="tbed13734-bib-0042" ref-type="ref">2020</xref>; Zhang, Lin, et al., <xref rid="tbed13734-bib-0101" ref-type="ref">2020</xref>).</p></sec></sec></sec><sec id="tbed13734-sec-0018"><label>3.4</label><title>Replication of the CoV&#x02010;19 genome</title><sec id="tbed13734-sec-0019"><label>3.4.1</label><title>RNA&#x02010;dependent RNA polymerase (RdRp)</title><p>Genome multiplication is critical in the life cycle of the virus and can be an attractive target for the intervention in the infection progress. RNA&#x02010;dependent RNA polymerase (RdRp) (nsp12) or RNA replicase is the most principal protein in the coronavirus replication/transcription complex (Gao et al., <xref rid="tbed13734-bib-0028" ref-type="ref">2020</xref>).</p><p>The anti&#x02010;viral agents of remdesivir, favipiravir and penciclovir can block the RNA&#x02010;dependent RNA polymerase (RdRp) of many RNA viruses, specially the influenza virus. Wang et al. determined the efficiency of these agents on infected Vero E6 cells with SARS&#x02010;CoV&#x02010;2 (Li &#x00026; De Clercq,&#x000a0;<xref rid="tbed13734-bib-0042" ref-type="ref">2020</xref>; Wang et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0087" ref-type="ref">2020</xref>; Zhang, Lin, et al., <xref rid="tbed13734-bib-0101" ref-type="ref">2020</xref>). The high concentrations of penciclovir (EC50&#x000a0;=&#x000a0;95.96&#x000a0;&#x003bc;M) and favipiravir (EC50&#x000a0;=&#x000a0;61.88&#x000a0;&#x003bc;M) were needed to decrease the viral infection, while remdesivir (EC50&#x000a0;=&#x000a0;0.77&#x000a0;&#x003bc;M) prevented the virus multiplication even at low concentrations.</p><p>After cell entry, remdesivir is metabolized into nucleoside triphosphate analogue via competing for ATP. Its incorporation by RdRp inhibits viral replication through pre&#x02010;mature termination of RNA synthesis. Importantly, remdesivir inhibits the viral replication in RNA viruses including positive and negative senses like NiV, EBOV, SARS, MERS, HCoV&#x02010;OC43, HCoV&#x02010;229E and SARS&#x02010;CoV&#x02010;2 in both in vitro and in vivo studies. Although delayed chain termination is a possible mechanism of remdesivir against EBOV with negative senses RNA, the action mechanism remains to be fully explicated (Gordon, Tchesnokov, Feng, Porter, &#x00026; G&#x000f6;tte, <xref rid="tbed13734-bib-0030" ref-type="ref">2020</xref>; Tchesnokov, Feng, Porter, &#x00026; G&#x000f6;tte, <xref rid="tbed13734-bib-0079" ref-type="ref">2019</xref>). Sheahan et al. recently introduced a ribonucleoside analogue, &#x003b2;&#x02010;D&#x02010;N<sup>4</sup>&#x02010;hydroxycytidine, with broad&#x02010;spectrum anti&#x02010;viral activity against SARS&#x02010;CoV&#x02010;2 and other coronaviruses with mutations in RdRp conferring increased resistance to remdesivir, indicating the risk of SARS&#x02010;CoV&#x02010;2 becoming clinically drug resistant (Sheahan et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0070" ref-type="ref">2020</xref>).</p></sec><sec id="tbed13734-sec-0020"><label>3.4.2</label><title>Helicase</title><p>Helicase (nsp13) is a critical protein with several functions required for virus replication containing two main domains; N&#x02010;terminal metal binding domain (MBD) and a conserved helicase domain at the C&#x02010;terminus (Hel). This enzyme unfolds the firm secondary structures of the genome in positive&#x02010;sense RNA viruses to increase the yield of its translation (Adedeji, Marchand, et al., <xref rid="tbed13734-bib-0001" ref-type="ref">2012</xref>). Despite the essential function of helicase in virus multiplication, limited potential suppressors of nsp13 have been reported so far (Adedeji, Singh, et al., <xref rid="tbed13734-bib-0002" ref-type="ref">2012</xref>; Shum &#x00026; Tanner,&#x000a0;<xref rid="tbed13734-bib-0071" ref-type="ref">2008</xref>).</p><p>A 1,2,4&#x02010;triazole derivative, SSYA10&#x02010;001, has shown an inhibitory effect on both helicases of SARS&#x02010; and MERS&#x02010;CoVs with 25 and 7&#x000a0;&#x003bc;M of the EC50 values, respectively (Adedeji et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0003" ref-type="ref">2014</xref>). In another research, Yu et al concluded that myricetin and scutellarein can suppress the helicase of SARS&#x02010;CoV (Yu et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0098" ref-type="ref">2012</xref>). The potent inhibition of SARS coronavirus replication and the helicase activity with EC50 of less than 10&#x000a0;&#x003bc;M is also reported by the Adamantane&#x02010;derived Bananins (Tanner et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0077" ref-type="ref">2005</xref>).</p></sec><sec id="tbed13734-sec-0021"><label>3.4.3</label><title>The peptidyl/prolyl isomerases (PPIases)</title><p>The 18&#x02010;kDa cytosolic cyclophilin A is a necessary cellular molecule needed for replication of RNA viruses including HIV (Luban, Bossolt, Franke, Kalpana, &#x00026; Goff,&#x000a0;<xref rid="tbed13734-bib-0050" ref-type="ref">1993</xref>), HCV (Watashi et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0088" ref-type="ref">2005</xref>), influenza A (Liu et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0047" ref-type="ref">2012</xref>) and also coronavirus. Cyclophilins (Cyps), belonging to the family of peptidyl&#x02010;prolyl isomerases (PPIases), conducts the rate&#x02010;limiting cis/trans isomerization step of proline&#x02010;preceding peptide bonds during the protein folding. The PPIase activity is blocked by cyclosporin A and its different analogues which are non&#x02010;immunosuppressive agents (de Wilde, Pham, Posthuma, &#x00026; Snijder,&#x000a0;<xref rid="tbed13734-bib-0021" ref-type="ref">2018</xref>) such as alisporivir (ALV; or Debio&#x02010;025) (Landrieu et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0039" ref-type="ref">2010</xref>), SCY&#x02010;635 (Hopkins et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0032" ref-type="ref">2010</xref>) andNIM811 (Ciechomska et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0015" ref-type="ref">2005</xref>).</p><p>There are various reports indicating the effect of Cyps (Pfefferle et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0058" ref-type="ref">2011</xref>; de Wilde et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0022" ref-type="ref">2011</xref>) and its derivatives (Carbajo&#x02010;Lozoya et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0011" ref-type="ref">2014</xref>; de Wilde et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0020" ref-type="ref">2017</xref>) on different genera of coronaviruses mainly MERS&#x02010;CoV, HCoV&#x02010;229E, HCoV&#x02010;NL63 and SARS&#x02010;CoV in cell culture which might be applicable on SARS&#x02010;CoV&#x02010;2 as well.</p></sec><sec id="tbed13734-sec-0022"><label>3.4.4</label><title>Nucleoside analogue inhibitors</title><p>Nucleoside analogues (dNTPs or rNTPs without 3&#x02032;&#x02010;OH group resulting in chain termination) are extensively applied for the hepatitis C virus (HCV), hepatitis B virus (HBV), HIV&#x02010;1 and HSV therapy. Compared to the other RNA viruses, the proofreading activity of RdRp by the capability of 3&#x02032; to 5&#x02032; exoribonuclease (nsp14) leads up to 20&#x02010;fold enhancement in the accuracy of replication. Thus, the enzyme of coronavirus is rather resistant to many nucleoside analogues including favipiravir (guanine analogue), ribavirin (guanosine analogue) and 5&#x02010;fluorouracil (pyrimidine analogue) (Harrison,&#x000a0;<xref rid="tbed13734-bib-0031" ref-type="ref">2020</xref>).</p><p>Remdesivir, (adenosine analogue) as a potent phosphoramidate prodrug, is effective against filoviruses, pneumoviruses and paramyxoviruses with two suggested mechanisms of action (Lo et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0048" ref-type="ref">2017</xref>). One is being as nucleoside analogue and the second is acting on viral RdRp. Accordingly, Peters et al evaluated the efficiency of some nucleoside analogues suggesting that compound 2 with EC50&#x000a0;&#x0003c;&#x000a0;10&#x000a0;&#x003bc;M was promising against HCoV&#x02010;NL63 (Peters et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0057" ref-type="ref">2015</xref>). The combinations of nucleotide analogues can mitigate the resistance mediated by mutations in the viral RdRp, perhaps by additive or synergistic interactions effect (Pruijssers &#x00026; Denison,&#x000a0;<xref rid="tbed13734-bib-0059" ref-type="ref">2019</xref>). Despite the proofreading activity, identifying nucleoside analogue inhibitors hold promise for the treatment of SARS&#x02010;CoV&#x02010;2.</p></sec></sec><sec id="tbed13734-sec-0023"><label>3.5</label><title>Viral protein assembly</title><p>Capsid proteins have a pivotal function in the assembly of the virus, and interfering with the structure or function of these key proteins can be a solid anti&#x02010;viral strategy. Coronaviruses are distinct from other coated viruses in that they are assembled in the endoplasmic reticulum and golgi intermediate compartment (ERGIC) as the intracellular membranes and transported out of the cell by exocytosis (Schoeman &#x00026; Fielding,&#x000a0;<xref rid="tbed13734-bib-0066" ref-type="ref">2019</xref>). Envelope proteins (E) are clearly important in assembly of coronaviruses, but their exact mechanistic role(s) is still not yet fully described (Schoeman &#x00026; Fielding,&#x000a0;<xref rid="tbed13734-bib-0066" ref-type="ref">2019</xref>). The major part of E protein is localized in intracellular trafficking and participates in coronavirus assembly, although it is expressed inside the infected cell in large quantities. The envelope protein (E) of coronaviruses (HCoV&#x02010;229E, Mouse hepatitis virus (MHV), IBV) mediates the assembly of virus and generates some cation&#x02010;selective ion channels that their function is not clear (Wilson, Mckinlay, Gage, &#x00026; Ewart,&#x000a0;<xref rid="tbed13734-bib-0089" ref-type="ref">2004</xref>). The involvement of E protein in pivotal stages of the viral life cycle makes SARS&#x02010;CoV&#x02010;2 lacking E protein, a promising vaccine candidate. Pharmacological blockage of its assembly with acylguanidine and cinnamoylguanidine reduced the SARS&#x02010;CoV and MHV viral titre by 76 and 88% at a concentration of 10&#x000a0;&#x000b5;M, respectively (Gage, Ewart, Wilson, Best, &#x00026; Premkumar, <xref rid="tbed13734-bib-0027" ref-type="ref">2007</xref>).</p><p>M protein is the other main structural proteins of SAR&#x02010;CoV&#x02010;2 determining the shape of the virus envelope. This protein also confirms the nucleocapsid stability, promotes viral assembly and encapsulates the viral genome. Qin et al. designed siRNAs that degrade M mRNA and block the expression of M protein in SARS&#x02010;associated coronavirus, proposing an approach for researches towards developing the new therapeutic agents for CoV infection (Qin, Zhao, Cao, &#x00026; Qi,&#x000a0;<xref rid="tbed13734-bib-0061" ref-type="ref">2007</xref>).</p><p>The inhibition of viral assemble is investigated for different types of viruses including moloney murine leukaemia virus (Mo&#x02010;MLV) (McNally, Wahlin, &#x00026; Canto&#x02010;Soler,&#x000a0;<xref rid="tbed13734-bib-0053" ref-type="ref">2010</xref>), classical swine fever virus (CSFV) (Zhou, Liu, &#x00026; Chen,&#x000a0;<xref rid="tbed13734-bib-0103" ref-type="ref">2008</xref>), HIV&#x02010;2 (Wu et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0092" ref-type="ref">1995</xref>), HIV&#x02010;1 (Li et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0043" ref-type="ref">2009</xref>), dengue virus type 2 (DENV2) (Qin et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0060" ref-type="ref">2005</xref>), HBV (Seo et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0068" ref-type="ref">2019</xref>) and influenza A (Liu et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0045" ref-type="ref">2014</xref>). However, no approved drug candidate or in clinical trial disparting the SARS&#x02010;CoV&#x02010;2 assembly is reported so far.</p></sec><sec id="tbed13734-sec-0024"><label>3.6</label><title>Cell release of the virus</title><p>Prevention of the release of the viruses from host cells as the last phase of the viral cycle is an attractive strategy to minimize the dissemination of the virus mainly in pandemics to limit the released viral load in the society. Drugs like zanamivir, oseltamivir, laninamivir octanoate and peramivir inhibit this step by targeting viral neuraminidase to block the release of the Influenza virus (De Clercq &#x00026; Li,&#x000a0;<xref rid="tbed13734-bib-0019" ref-type="ref">2016</xref>). Bone marrow matrix antigen 2 (BST&#x02010;2), also known as tetherin or CD 317, was found as the factor causing a defect in virion release of HIV&#x02010;1 mutants without the vpu accessory gene (Van Damme et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0083" ref-type="ref">2008</xref>).</p><p>One of the coronavirus virulence factors is ORF7a that inhibits the bone marrow matrix antigen 2 (BST&#x02010;2) (Taylor et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0078" ref-type="ref">2015</xref>) related to its escape from the innate immune system by host mRNA degradation and interferon production inhibition. BST&#x02010;2 is constitutively expressed in plasma cells, mature B cells and type I interferon&#x02010;producing cells that can hinder the liberation of biosynthesized coronavirus from hosts. The evidence implied that ORF7a can be speculated as a potential target for anti&#x02010;viral drug discovery of SARS&#x02010;CoV&#x02010;2.</p></sec></sec><sec id="tbed13734-sec-0025"><label>4</label><title>CONCLUDING REMARKS</title><p>In the preceding 20&#x000a0;years, two novel coronaviruses have been emerged mainly causing the severe acute respiratory syndrome coronavirus (SARS&#x02010;CoV) and Middle East respiratory syndrome coronavirus (MERS&#x02010;CoV) responsible for the epidemics in 2002 and 2012, respectively (World Health Organization,&#x000a0;<xref rid="tbed13734-bib-0090" ref-type="ref">2003</xref>, <xref rid="tbed13734-bib-0091" ref-type="ref">2013</xref>). Since the pandemic spread of novel coronavirus (SARS&#x02010;CoV&#x02010;2) and the rapidly increasing number of patients by minutes (473,061 deaths at the time of writing this article by 24 June 2020, unfortunately), the focus has been on the assessments to recruit the existing anti&#x02010;viral compounds which must be complemented by the new drug discovery programmes in the future. Nevertheless, the current urgent demand is being addressed by the clinical trials of 31 drugs to approve the effectiveness of the existing anti&#x02010;viral drugs on SARS&#x02010;CoV&#x02010;2.</p><p>The potential molecular targets in anti&#x02010;SARS&#x02010;CoV&#x02010;2 drug discovery are surveyed in this paper that can be employed in HTS programmes for systematic drug discovery for SARS&#x02010;CoV&#x02010;2 infection. Negligible knowledge is still available on the biology of SARS&#x02010;CoV&#x02010;2 specially, viral protein synthesis and assembly and most of what we know have been for the last 7&#x000a0;months. Due to the high virus transmission and the global spread of coronavirus, the foremost controversial issue is the mitigation of its pathogenicity using the existing anti&#x02010;viral compounds. Therefore, in silico or practical screening of molecular targets is being conducted on structural information obtained from all major variants of the virus. Although the ongoing clinical trials are evaluating the potential treatments of more than 31 drugs, there are currently no specifically certified drugs or vaccines for SARS&#x02010;CoV&#x02010;2.and the single drug in the frontline may/may not potentially be recognized effective after the completion of the clinical trials. In addition to the above approach, the detailed study of the viral life cycle can lead to assigning some even more effective drug targets. In this direction, some drug targets based on bioinformatics analysis and relative similarities of this new virus with other members of its family like host cell receptors, spike glycoproteins, papain&#x02010;like and 3C&#x02010;like protease, RdRp have been documented so far. However, an approximately half of the potent drug candidates and nearly one&#x02010;third of the drugs registered on the <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> webpage solely inhibit proteases affecting the replicase protein expression step in the viral life cycle.</p><p>While full&#x02010;length S proteins of SARS&#x02010;CoV&#x02010;2 and SARS&#x02010;CoV have up to 76% similarities in amino acid sequences, the N&#x02010;terminal domain that binds to the receptor shows only 53.5% of homology reflecting its potential to bind different sugars. Therefore, emphasizing on other virus entry&#x02010;related factors like cathepsin seems valuable for SARS&#x02010;CoV&#x02010;2 drug discovery. In fact, host proteases cathepsin L and TMPRSS2 prepare the SARS&#x02010;CoV&#x02010;2 S protein for cell entry (Walls et&#x000a0;al.,&#x000a0;<xref rid="tbed13734-bib-0085" ref-type="ref">2020</xref>). Considering the results of repurposing strategies and clinical tests until now, remdesivir seems a promising dual&#x02010;acting drug (inhibiting viral RNA polymerases and 3C&#x02010;like main protease). Studies conducted so far suggest the drug might cause some minor side effects including nausea, liver damage and cardiopulmonary failure. Beyond the ongoing studies of remdesivir, now researchers are hoping to explore whether the remdesivir can be combined with other anti&#x02010;viral drugs for making a more effective SARS&#x02010;CoV&#x02010;2 combating cocktail. Six clinical trials are currently underway to specify testing remdesivir with other medicines, according to Informa Pharma Intelligence. Nevertheless, HIV protease inhibitors (ritonavir/lopinavir/ASC09), favipiravir and chloroquine need further investigations.</p></sec><sec id="tbed13734-sec-0026"><label>5</label><title>FUTURE DIRECTIONS</title><p>As we proceed with the current molecular docking studies and presuming the effectiveness of the existing anti&#x02010;viral compounds, the de novo drug discovery will join to evaluate the modulation of the new molecular targets of SARS&#x02010;CoV&#x02010;2 in bioassay platforms which were discussed above. To accelerate the long, costly and rigorous process of drug discovery, high&#x02010;throughput methods and high&#x02010;content screening methods can be employed. However, by the immediate global need for drugs to control the SARS&#x02010;CoV&#x02010;2 infection drug search is currently pursued by the repurposing approach. Accordingly, the critical viral life cycle steps like entry, genome and protein synthesis reflect the multiple drug target groups not limited to 3cl pro and RdRp that can be addressed by the conventional de novo strategy of drug discovery. Assembly and release inhibitors are less considered steps in SARS&#x02010;CoV&#x02010;2 life cycle for its drug discovery. While most of the drug cases for SARS&#x02010;CoV&#x02010;2 are registered for the control purpose rather than prophylaxis; S protein, integrins and ACE2 targets are of value for drug repurposing or discovery programmes to hinder the viral entry and fusion process. Considering the fact that the primary goal of all viruses is to deliver and replicate their genome to the competent host cells, blocking angiotensin&#x02010;converting enzyme 2 (ACE2), cathepsin L, 3Cl protease and RdRp are suggested to be promising targets for anti&#x02010;SARS&#x02010;CoV&#x02010;2 drug discovery.</p></sec><sec sec-type="COI-statement" id="tbed13734-sec-0028"><title>CONFLICT OF INTEREST</title><p>No conflict of interest is declared on the data collected and interpreted in this paper.</p></sec><sec id="tbed13734-sec-0029"><title>ETHICAL APPROVAL</title><p>The authors declare that no ethical was needed for the current non&#x02010;experimental paper.</p></sec></body><back><ack id="tbed13734-sec-0027"><title>ACKNOWLEDGEMENTS</title><p>This paper was not funded by any organization.</p></ack><sec sec-type="data-availability" id="tbed13734-sec-0031"><title>DATA AVAILABILITY STATEMENT</title><p>The paper is a review and does not have original experimental data to make them available.</p></sec><ref-list content-type="cited-references" id="tbed13734-bibl-0001"><title>REFERENCES</title><ref id="tbed13734-bib-0001"><mixed-citation publication-type="journal" id="tbed13734-cit-0001">
<string-name>
<surname>Adedeji</surname>, <given-names>A. O.</given-names>
</string-name>, <string-name>
<surname>Marchand</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>te Velthuis</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Snijder</surname>, <given-names>E. J.</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Eoff</surname>, <given-names>R. L.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Sarafianos</surname>, <given-names>S. G.</given-names>
</string-name> (<year>2012</year>). <article-title>Mechanism of nucleic acid unwinding by SARS&#x02010;CoV helicase</article-title>. <source xml:lang="en">PLoS One</source>, <volume>7</volume>, <elocation-id>e36521</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0036521</pub-id>
<pub-id pub-id-type="pmid">22615777</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0002"><mixed-citation publication-type="journal" id="tbed13734-cit-0002">
<string-name>
<surname>Adedeji</surname>, <given-names>A. O.</given-names>
</string-name>, <string-name>
<surname>Singh</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Calcaterra</surname>, <given-names>N. E.</given-names>
</string-name>, <string-name>
<surname>DeDiego</surname>, <given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Enjuanes</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>, <given-names>S.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Sarafianos</surname>, <given-names>S. G.</given-names>
</string-name> (<year>2012</year>). <article-title>Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase</article-title>. <source xml:lang="en">Antimicrobial Agents and Chemotherapy</source>, <volume>56</volume>, <fpage>4718</fpage>&#x02013;<lpage>4728</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00957-12</pub-id>
<pub-id pub-id-type="pmid">22733076</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0003"><mixed-citation publication-type="journal" id="tbed13734-cit-0003">
<string-name>
<surname>Adedeji</surname>, <given-names>A. O.</given-names>
</string-name>, <string-name>
<surname>Singh</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Kassim</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Coleman</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Elliott</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>, <given-names>S. R.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Sarafianos</surname>, <given-names>S. G.</given-names>
</string-name> (<year>2014</year>). <article-title>Evaluation of SSYA10&#x02010;001 as a replication inhibitor of SARS, MHV and MERS coronaviruses</article-title>. <source xml:lang="en">Antimicrobial Agents and Chemotherapy</source>, <volume>58</volume>, <fpage>4894</fpage>&#x02013;<lpage>4898</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.02994-14</pub-id>
<pub-id pub-id-type="pmid">24841268</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0004"><mixed-citation publication-type="journal" id="tbed13734-cit-0004">
<string-name>
<surname>Adem</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Eyupoglu</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Sarfraz</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Rasul</surname>, <given-names>A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Ali</surname>, <given-names>M.</given-names>
</string-name> (<year>2020</year>). <article-title>Identification of potent COVID&#x02010;19 main protease (Mpro) inhibitors from natural polyphenols: An in silico strategy unveils a hope against CORONA</article-title>. <source xml:lang="en">Preprints</source>. <pub-id pub-id-type="doi">10.20944/preprints202003.0333.v1</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0005"><mixed-citation publication-type="journal" id="tbed13734-cit-0005">
<string-name>
<surname>Aly</surname>, <given-names>O. M.</given-names>
</string-name> (<year>2020</year>). <article-title>Molecular docking reveals the potential of aliskiren, dipyridamole, mopidamol, rosuvastatin, rolitetracycline and metamizole to inhibit COVID&#x02010;19 virus main protease</article-title>. <source xml:lang="en">ChemRxiv</source>. Preprint. <pub-id pub-id-type="doi">10.26434/chemrxiv.12061302.v1</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0006"><mixed-citation publication-type="journal" id="tbed13734-cit-0006">
<string-name>
<surname>AminJafari</surname>, <given-names>A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Ghasemi</surname>, <given-names>S.</given-names>
</string-name> (<year>2020</year>). <article-title>The possible of immunotherapy for COVID&#x02010;19: A systematic review</article-title>. <source xml:lang="en">International Immunopharmacology</source>, <volume>83</volume>, <fpage>106455</fpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2020.106455</pub-id>
<pub-id pub-id-type="pmid">32272396</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0007"><mixed-citation publication-type="journal" id="tbed13734-cit-0007">
<string-name>
<surname>Aranda Abreu</surname>, <given-names>G. E.</given-names>
</string-name>, <string-name>
<surname>Hern&#x000e1;ndez Aguilar</surname>, <given-names>M. E.</given-names>
</string-name>, <string-name>
<surname>Herrera Covarrubias</surname>, <given-names>D.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Rojas Dur&#x000e1;n</surname>, <given-names>F.</given-names>
</string-name> (<year>2020</year>). <article-title>Amantadine as a drug to mitigate the effects of COVID&#x02010;19</article-title>. <source xml:lang="en">Medical Hypotheses</source>, <volume>140</volume>, <fpage>109755</fpage>
<pub-id pub-id-type="doi">10.1016/j.mehy.2020.109755</pub-id>
<pub-id pub-id-type="pmid">32361100</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0008"><mixed-citation publication-type="journal" id="tbed13734-cit-0008">
<string-name>
<surname>Arya</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Das</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Prashar</surname>, <given-names>V.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Kumar</surname>, <given-names>M.</given-names>
</string-name> (<year>2020</year>). <article-title>Potential inhibitors against papain&#x02010;like protease of novel coronavirus (SARS&#x02010;CoV&#x02010;2) from FDA approved drugs</article-title>. <source xml:lang="en">ChemRxiv</source>. Preprint.</mixed-citation></ref><ref id="tbed13734-bib-0009"><mixed-citation publication-type="journal" id="tbed13734-cit-0009">
<string-name>
<surname>Balgi</surname>, <given-names>A. D.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>, <given-names>D. Y. H.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Pfeifer</surname>, <given-names>T. A.</given-names>
</string-name>, <string-name>
<surname>Shimizu</surname>, <given-names>Y.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Roberge</surname>, <given-names>M.</given-names>
</string-name> (<year>2013</year>). <article-title>Inhibitors of the influenza A virus M2 proton channel discovered using a high&#x02010;throughput yeast growth restoration assay</article-title>. <source xml:lang="en">PLoS One</source>, <volume>8</volume>, <elocation-id>e55271</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0055271</pub-id>
<pub-id pub-id-type="pmid">23383318</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0010"><mixed-citation publication-type="journal" id="tbed13734-cit-0010">
<string-name>
<surname>Bosch</surname>, <given-names>B. J.</given-names>
</string-name>, <string-name>
<surname>van der Zee</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>de Haan</surname>, <given-names>C. A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Rottier</surname>, <given-names>P. J.</given-names>
</string-name> (<year>2003</year>). <article-title>The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex</article-title>. <source xml:lang="en">Journal of Virology</source>, <volume>77</volume>, <fpage>8801</fpage>&#x02013;<lpage>8811</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.77.16.8801-8811.2003</pub-id>
<pub-id pub-id-type="pmid">12885899</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0011"><mixed-citation publication-type="journal" id="tbed13734-cit-0011">
<string-name>
<surname>Carbajo&#x02010;Lozoya</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Ma&#x02010;Lauer</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Male&#x00161;evi&#x00107;</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Theuerkorn</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kahlert</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Prell</surname>, <given-names>E.</given-names>
</string-name>, &#x02026; <string-name>
<surname>von Brunn</surname>, <given-names>A.</given-names>
</string-name> (<year>2014</year>). <article-title>Human coronavirus NL63 replication is cyclophilin A&#x02010;dependent and inhibited by non&#x02010;immunosuppressive cyclosporine A&#x02010;derivatives including Alisporivir</article-title>. <source xml:lang="en">Virus Research</source>, <volume>184</volume>, <fpage>44</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.02.010</pub-id>
<pub-id pub-id-type="pmid">24566223</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0012"><mixed-citation publication-type="book" id="tbed13734-cit-0012">
<string-name>
<surname>Cascella</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Rajnik</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Cuomo</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Dulebohn</surname>, <given-names>S. C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Di Napoli</surname>, <given-names>R.</given-names>
</string-name> (<year>2020</year>, April 6). <source xml:lang="en">Features, evaluation and treatment coronavirus (COVID&#x02010;19)</source> [in StatPearls]. Retrieved from <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK554776/">https://www.ncbi.nlm.nih.gov/books/NBK554776/</ext-link>
</mixed-citation></ref><ref id="tbed13734-bib-0013"><mixed-citation publication-type="journal" id="tbed13734-cit-0013">
<string-name>
<surname>Chan</surname>, <given-names>J.&#x02010;F.&#x02010;W.</given-names>
</string-name>, <string-name>
<surname>Kok</surname>, <given-names>K. H.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Chu</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>To</surname>, <given-names>K.&#x02010;K.&#x02010;W.</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>, <given-names>S.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Yuen</surname>, <given-names>K. Y.</given-names>
</string-name> (<year>2020</year>). <article-title>Genomic characterization of the 2019 novel human&#x02010;pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title>. <source xml:lang="en">Emerging Microbes &#x00026; Infections</source>, <volume>9</volume>, <fpage>221</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2020.1719902</pub-id>
<pub-id pub-id-type="pmid">31987001</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0014"><mixed-citation publication-type="journal" id="tbed13734-cit-0014">
<string-name>
<surname>Chen</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Fu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Qu</surname>, <given-names>H.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Huang</surname>, <given-names>X.</given-names>
</string-name> (<year>2020</year>). <article-title>Identification of the immunodominant neutralizing regions in the spike glycoprotein of porcine deltacoronavirus</article-title>. <source xml:lang="en">Virus Research</source>, <volume>276</volume>, <fpage>197834</fpage>
<pub-id pub-id-type="doi">10.1016/j.virusres.2019.197834</pub-id>
<pub-id pub-id-type="pmid">31816342</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0015"><mixed-citation publication-type="journal" id="tbed13734-cit-0015">
<string-name>
<surname>Ciechomska</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Legat</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Golab</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Wesolowska</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Kurzaj</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Mackiewicz</surname>, <given-names>A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Kaminska</surname>, <given-names>B.</given-names>
</string-name> (<year>2005</year>). <article-title>Cyclosporine A and its non&#x02010;immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in <italic>in vitro</italic> and <italic>in vivo</italic> studies</article-title>. <source xml:lang="en">International Journal of Cancer</source>, <volume>117</volume>, <fpage>59</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.21153</pub-id>
<pub-id pub-id-type="pmid">15880533</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0016"><mixed-citation publication-type="journal" id="tbed13734-cit-0016">
<string-name>
<surname>Contini</surname>, <given-names>A.</given-names>
</string-name> (<year>2020</year>). <article-title>Virtual screening of an FDA approved drugs database on two COVID&#x02010;19 coronavirus proteins</article-title>. <source xml:lang="en">ChemRxiv</source>. Preprint. <pub-id pub-id-type="doi">10.26434/chemrxiv.11847381.v1</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0017"><mixed-citation publication-type="journal" id="tbed13734-cit-0017">
<string-name>
<surname>Coutard</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Valle</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>de Lamballerie</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Canard</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Seidah</surname>, <given-names>N. G.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Decroly</surname>, <given-names>E.</given-names>
</string-name> (<year>2020</year>). <article-title>The spike glycoprotein of the new coronavirus SARS&#x02010;COV&#x02010;2 contains a furin&#x02010;like cleavage site absent in CoV of the same clade</article-title>. <source xml:lang="en">Antiviral Research</source>, <volume>176</volume>, <fpage>104742</fpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104742</pub-id>
<pub-id pub-id-type="pmid">32057769</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0018"><mixed-citation publication-type="journal" id="tbed13734-cit-0018">
<string-name>
<surname>Dastan</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Tabarsi</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Marjani</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Moniri</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hashemian</surname>, <given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Tavakoli&#x02010;Ardakani</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Saffaei</surname>, <given-names>A.</given-names>
</string-name> (<year>2020</year>). <article-title>Thalidomide against coronavirus disease 2019 (COVID&#x02010;19): A medicine with a thousand faces</article-title>. <source xml:lang="en">Iranian Journal of Pharmaceutical Research</source>, <volume>19</volume>, <fpage>1</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.22037/IJPR.2020.113369.14259</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0019"><mixed-citation publication-type="journal" id="tbed13734-cit-0019">
<string-name>
<surname>De Clercq</surname>, <given-names>E.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Li</surname>, <given-names>G.</given-names>
</string-name> (<year>2016</year>). <article-title>Approved antiviral drugs over the past 50 years</article-title>. <source xml:lang="en">Clinical Microbiology Reviews</source>, <volume>29</volume>, <fpage>695</fpage>&#x02013;<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00102-15</pub-id>
<pub-id pub-id-type="pmid">27281742</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0020"><mixed-citation publication-type="journal" id="tbed13734-cit-0020">
<string-name>
<surname>de Wilde</surname>, <given-names>A. H.</given-names>
</string-name>, <string-name>
<surname>Falzarano</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Zevenhoven&#x02010;Dobbe</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<surname>Beugeling</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Fett</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Martellaro</surname>, <given-names>C.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Snijder</surname>, <given-names>E. J.</given-names>
</string-name> (<year>2017</year>). <article-title>Alisporivir inhibits MERS&#x02010;and SARS&#x02010;coronavirus replication in cell culture, but not SARS&#x02010;coronavirus infection in a mouse model</article-title>. <source xml:lang="en">Virus Research</source>, <volume>228</volume>, <fpage>7</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2016.11.011</pub-id>
<pub-id pub-id-type="pmid">27840112</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0021"><mixed-citation publication-type="journal" id="tbed13734-cit-0021">
<string-name>
<surname>de Wilde</surname>, <given-names>A. H.</given-names>
</string-name>, <string-name>
<surname>Pham</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Posthuma</surname>, <given-names>C. C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Snijder</surname>, <given-names>E. J.</given-names>
</string-name> (<year>2018</year>). <article-title>Cyclophilins and cyclophilin inhibitors in nidovirus replication</article-title>. <source xml:lang="en">Virology</source>, <volume>522</volume>, <fpage>46</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2018.06.011</pub-id>
<pub-id pub-id-type="pmid">30014857</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0022"><mixed-citation publication-type="journal" id="tbed13734-cit-0022">
<string-name>
<surname>de Wilde</surname>, <given-names>A. H.</given-names>
</string-name>, <string-name>
<surname>Zevenhoven&#x02010;Dobbe</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<surname>van der Meer</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Thiel</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Narayanan</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Makino</surname>, <given-names>S.</given-names>
</string-name>, &#x02026; <string-name>
<surname>van Hemert</surname>, <given-names>M. J.</given-names>
</string-name> (<year>2011</year>). <article-title>Cyclosporin A inhibits the replication of diverse coronaviruses</article-title>. <source xml:lang="en">The Journal of General Virology</source>, <volume>92</volume>, <fpage>2542</fpage>
<pub-id pub-id-type="doi">10.1099/vir.0.034983-0</pub-id>
<pub-id pub-id-type="pmid">21752960</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0023"><mixed-citation publication-type="journal" id="tbed13734-cit-0023">
<string-name>
<surname>Dong</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Xie</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Sui</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>L.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Peng</surname>, <given-names>G.</given-names>
</string-name> (<year>2020</year>). <article-title>Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen&#x02010;activated protein kinase pathways</article-title>. <source xml:lang="en">Antiviral Research</source>, <volume>173</volume>, <fpage>104651</fpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104651</pub-id>
<pub-id pub-id-type="pmid">31751591</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0024"><mixed-citation publication-type="journal" id="tbed13734-cit-0024">
<string-name>
<surname>Donoghue</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hsieh</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Baronas</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Godbout</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Gosselin</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Stagliano</surname>, <given-names>N.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Acton</surname>, <given-names>S.</given-names>
</string-name> (<year>2000</year>). <article-title>A novel angiotensin&#x02010;converting enzyme&#x02010;related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1&#x02013;9</article-title>. <source xml:lang="en">Circulation Research</source>, <volume>87</volume>, <fpage>e1</fpage>&#x02013;<lpage>e9</lpage>. <pub-id pub-id-type="doi">10.1161/01.res.87.5.e1</pub-id>
<pub-id pub-id-type="pmid">10969042</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0025"><mixed-citation publication-type="journal" id="tbed13734-cit-0025">
<string-name>
<surname>Elfiky</surname>, <given-names>A. A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Ibrahim</surname>, <given-names>N. S.</given-names>
</string-name> (<year>2020</year>). <article-title>Anti&#x02010;SARS and anti&#x02010;HCV drugs repurposing against the papain&#x02010;like protease of the newly emerged coronavirus (SARS&#x02010;COV&#x02010;2)</article-title>. <source xml:lang="en">Research Square</source>, Preprint. <pub-id pub-id-type="doi">10.21203/rs.2.23280/v1</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0026"><mixed-citation publication-type="journal" id="tbed13734-cit-0026">
<string-name>
<surname>Fehr</surname>, <given-names>A. R.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Perlman</surname>, <given-names>S.</given-names>
</string-name> (<year>2015</year>). <article-title>Coronaviruses: An overview of their replication and pathogenesis in Coronaviruses</article-title>. <source xml:lang="en">Springer</source>, <volume>1282</volume>, <fpage>1</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0027"><mixed-citation publication-type="book" id="tbed13734-cit-0027">
<string-name>
<surname>Gage</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Ewart</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Best</surname>, <given-names>W.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Premkumar</surname>, <given-names>A.</given-names>
</string-name> (<year>2007</year>). <source xml:lang="en">Antiviral compounds and methods</source> [Google Patents. No, US20020111382A1]. Retrieved from <ext-link ext-link-type="uri" xlink:href="https://patents.google.com/patent/US20020111382A1/en">https://patents.google.com/patent/US20020111382A1/en</ext-link>
</mixed-citation></ref><ref id="tbed13734-bib-0028"><mixed-citation publication-type="journal" id="tbed13734-cit-0028">
<string-name>
<surname>Gao</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Yan</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Cao</surname>, <given-names>L.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name> (<year>2020</year>). <article-title>Structure of the RNA&#x02010;dependent RNA polymerase from COVID&#x02010;19 virus</article-title>. <source xml:lang="en">Science</source>, <volume>368</volume>, <fpage>779</fpage>&#x02013;<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb7498</pub-id>
<pub-id pub-id-type="pmid">32277040</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0029"><mixed-citation publication-type="journal" id="tbed13734-cit-0029">
<string-name>
<surname>Garc&#x000ed;a&#x02010;Serradilla</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Risco</surname>, <given-names>C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Pacheco</surname>, <given-names>B.</given-names>
</string-name> (<year>2019</year>). <article-title>Drug repurposing for new, efficient, broad spectrum antivirals</article-title>. <source xml:lang="en">Virus Research</source>, <volume>15</volume>, <fpage>22</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2019.02.011</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0030"><mixed-citation publication-type="journal" id="tbed13734-cit-0030">
<string-name>
<surname>Gordon</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Tchesnokov</surname>, <given-names>E. P.</given-names>
</string-name>, <string-name>
<surname>Feng</surname>, <given-names>J. Y.</given-names>
</string-name>, <string-name>
<surname>Porter</surname>, <given-names>D. P.</given-names>
</string-name>, &#x00026; <string-name>
<surname>G&#x000f6;tte</surname>, <given-names>M.</given-names>
</string-name> (<year>2020</year>). <article-title>The antiviral compound remdesivir potently inhibits RNA&#x02010;dependent RNA polymerase from Middle East respiratory syndrome coronavirus</article-title>. <source xml:lang="en">Journal of Biological Chemistry</source>, <volume>295</volume>, <fpage>4773</fpage>&#x02013;<lpage>4779</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.AC120.013056</pub-id>
<pub-id pub-id-type="pmid">32094225</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0031"><mixed-citation publication-type="journal" id="tbed13734-cit-0031">
<string-name>
<surname>Harrison</surname>, <given-names>C.</given-names>
</string-name> (<year>2020</year>). <article-title>Coronavirus puts drug repurposing on the fast track</article-title>. <source xml:lang="en">Nature Biotechnology</source>, <volume>38</volume>, <fpage>379</fpage>&#x02013;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1038/d41587-020-00003-1</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0032"><mixed-citation publication-type="journal" id="tbed13734-cit-0032">
<string-name>
<surname>Hopkins</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Scorneaux</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Murray</surname>, <given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Wring</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Smitley</surname>, <given-names>C.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Ribeill</surname>, <given-names>Y.</given-names>
</string-name> (<year>2010</year>). <article-title>SCY&#x02010;635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro</article-title>. <source xml:lang="en">Antimicrobial Agents and Chemotherapy</source>, <volume>54</volume>, <fpage>660</fpage>&#x02013;<lpage>672</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00660-09</pub-id>
<pub-id pub-id-type="pmid">19933795</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0033"><mixed-citation publication-type="journal" id="tbed13734-cit-0033">
<string-name>
<surname>Jilg</surname>, <given-names>N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Chung</surname>, <given-names>R. T.</given-names>
</string-name> (<year>2012</year>). <article-title>Adding to the toolbox: Receptor tyrosine kinases as potential targets in the treatment of hepatitis C</article-title>. <source xml:lang="en">Journal of Hepatology</source>, <volume>56</volume>, <fpage>282</fpage>&#x02013;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2011.06.020</pub-id>
<pub-id pub-id-type="pmid">21784050</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0034"><mixed-citation publication-type="journal" id="tbed13734-cit-0034">
<string-name>
<surname>Jin</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Du</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Deng</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>Y.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Duan</surname>, <given-names>Y.</given-names>
</string-name> (<year>2020</year>). <article-title>Structure of Mpro from SARS&#x02010;CoV&#x02010;2 and discovery of its inhibitors</article-title>. <source xml:lang="en">Nature</source>, <volume>582</volume>, <fpage>289</fpage>&#x02013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id>
<pub-id pub-id-type="pmid">32272481</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0035"><mixed-citation publication-type="journal" id="tbed13734-cit-0035">
<string-name>
<surname>Khalili</surname>, <given-names>J. S.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Mak</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Yan</surname>, <given-names>Y.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Zhu</surname>, <given-names>Y.</given-names>
</string-name> (<year>2020</year>). <article-title>Novel coronavirus treatment with ribavirin: Groundwork for evaluation concerning COVID&#x02010;19</article-title>. <source xml:lang="en">Journal of Medical Virology</source>, <volume>92</volume>, <fpage>740</fpage>&#x02013;<lpage>746</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25798</pub-id>
<pub-id pub-id-type="pmid">32227493</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0036"><mixed-citation publication-type="journal" id="tbed13734-cit-0036">
<string-name>
<surname>Kilianski</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Mielech</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<surname>Deng</surname>, <given-names>X.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Baker</surname>, <given-names>S. C.</given-names>
</string-name> (<year>2013</year>). <article-title>Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain&#x02010;like and 3C&#x02010;like proteases using luciferase&#x02010;based biosensors</article-title>. <source xml:lang="en">Journal of Virology</source>, <volume>87</volume>, <fpage>11955</fpage>&#x02013;<lpage>11962</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02105-13</pub-id>
<pub-id pub-id-type="pmid">23986593</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0037"><mixed-citation publication-type="journal" id="tbed13734-cit-0037">
<string-name>
<surname>Kuba</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Imai</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Rao</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Gao</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Guo</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Guan</surname>, <given-names>B.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Penninger</surname>, <given-names>J. M.</given-names>
</string-name> (<year>2005</year>). <article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus&#x02010;induced lung injury</article-title>. <source xml:lang="en">Nature Medicine</source>, <volume>11</volume>, <fpage>875</fpage>&#x02013;<lpage>879</lpage>. <pub-id pub-id-type="doi">10.1038/nm1267</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0038"><mixed-citation publication-type="journal" id="tbed13734-cit-0038">
<string-name>
<surname>Kumar</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Liang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Parslow</surname>, <given-names>T. G.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Liang</surname>, <given-names>Y.</given-names>
</string-name> (<year>2011</year>). <article-title>Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication</article-title>. <source xml:lang="en">Journal of Virology</source>, <volume>85</volume>, <fpage>2818</fpage>&#x02013;<lpage>2827</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01969-10</pub-id>
<pub-id pub-id-type="pmid">21209112</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0039"><mixed-citation publication-type="journal" id="tbed13734-cit-0039">
<string-name>
<surname>Landrieu</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Hanoulle</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Bonachera</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Hamel</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Sibille</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Yin</surname>, <given-names>Y.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Lippens</surname>, <given-names>G.</given-names>, </string-name>(<year>2010</year>). <article-title>Structural basis for the non&#x02010;immunosuppressive character of the cyclosporin A analogue Debio 025</article-title>. <source xml:lang="en">Biochemistry</source>, <volume>49</volume>, <fpage>4679</fpage>&#x02013;<lpage>4686</lpage>. <pub-id pub-id-type="doi">10.1021/bi1003266</pub-id>
<pub-id pub-id-type="pmid">20423153</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0040"><mixed-citation publication-type="journal" id="tbed13734-cit-0040">
<string-name>
<surname>Lemmon</surname>, <given-names>M. A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Schlessinger</surname>, <given-names>J.</given-names>
</string-name> (<year>2010</year>). <article-title>Cell signaling by receptor tyrosine kinases</article-title>. <source xml:lang="en">Cell</source>, <volume>141</volume>, <fpage>1117</fpage>&#x02013;<lpage>1134</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2010.06.011</pub-id>
<pub-id pub-id-type="pmid">20602996</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0041"><mixed-citation publication-type="journal" id="tbed13734-cit-0041">
<string-name>
<surname>Ley</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Rivera&#x02010;Nieves</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Sandborn</surname>, <given-names>W. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Shattil</surname>, <given-names>S.</given-names>
</string-name> (<year>2016</year>). <article-title>Integrin&#x02010;based therapeutics: Biological basis, clinical use and new drugs</article-title>. <source xml:lang="en">Nature Reviews Drug Discovery</source>, <volume>15</volume>, <fpage>173</fpage>
<pub-id pub-id-type="doi">10.1038/nrd.2015.10</pub-id>
<pub-id pub-id-type="pmid">26822833</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0042"><mixed-citation publication-type="journal" id="tbed13734-cit-0042">
<string-name>
<surname>Li</surname>, <given-names>G.</given-names>
</string-name>, &#x00026; <string-name>
<surname>De Clercq</surname>, <given-names>E.</given-names>
</string-name> (<year>2020</year>). <article-title>Therapeutic options for the 2019 novel coronavirus (2019&#x02010;nCoV)</article-title>. <source xml:lang="en">Nature Reviews Drug Discovery</source>, <volume>19</volume>, <fpage>149</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1038/d41573-020-00016-0</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0043"><mixed-citation publication-type="journal" id="tbed13734-cit-0043">
<string-name>
<surname>Li</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Tan</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Tang</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hewlett</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Pang</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>He</surname>, <given-names>M.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Yang</surname>, <given-names>M.</given-names>
</string-name> (<year>2009</year>). <article-title>Discovery of dual inhibitors targeting both HIV&#x02010;1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid</article-title>. <source xml:lang="en">Bioorganic &#x00026; Medicinal Chemistry</source>, <volume>17</volume>, <fpage>3177</fpage>&#x02013;<lpage>3188</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2009.02.051</pub-id>
<pub-id pub-id-type="pmid">19328002</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0044"><mixed-citation publication-type="journal" id="tbed13734-cit-0044">
<string-name>
<surname>Li</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Luk</surname>, <given-names>H. K.H</given-names>
</string-name>, <string-name>
<surname>Lau</surname>, <given-names>S. K.P</given-names>
</string-name>, &#x00026; <string-name>
<surname>Woo</surname>, <given-names>P. C.Y</given-names>
</string-name> (<year>2019</year>). <article-title>Human Coronaviruses: General Features</article-title>. <source xml:lang="en">Reference Module in Biomedical Sciences</source>, 2019. <pub-id pub-id-type="doi">10.1016/B978-0-12-801238-3.95704-0</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0045"><mixed-citation publication-type="journal" id="tbed13734-cit-0045">
<string-name>
<surname>Liu</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Xiang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Guo</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Pei</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Kitazato</surname>, <given-names>K.</given-names>
</string-name> (<year>2014</year>). <article-title>Cofilin&#x02010;1 is involved in regulation of actin reorganization during influenza A virus assembly and budding</article-title>. <source xml:lang="en">Biochemical and Biophysical Research Communications</source>, <volume>453</volume>, <fpage>821</fpage>&#x02013;<lpage>825</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2014.10.036</pub-id>
<pub-id pub-id-type="pmid">25450354</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0046"><mixed-citation publication-type="journal" id="tbed13734-cit-0046">
<string-name>
<surname>Liu</surname>, <given-names>X.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Wang</surname>, <given-names>X. J.</given-names>
</string-name> (<year>2020</year>). <article-title>Potential inhibitors for 2019&#x02010;nCoV coronavirus M protease from clinically approved medicines</article-title>. <source xml:lang="en">BioRxiv</source>, Preprint. <pub-id pub-id-type="doi">10.1101/2020.01.29.924100</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0047"><mixed-citation publication-type="journal" id="tbed13734-cit-0047">
<string-name>
<surname>Liu</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Liu</surname>, <given-names>W.</given-names>
</string-name> (<year>2012</year>). <article-title>Cyclophilin A restricts influenza A virus replication through degradation of the M1 protein</article-title>. <source xml:lang="en">PLoS One</source>, <volume>7</volume>, <elocation-id>e31063</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0031063</pub-id>
<pub-id pub-id-type="pmid">22347431</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0048"><mixed-citation publication-type="journal" id="tbed13734-cit-0048">
<string-name>
<surname>Lo</surname>, <given-names>M. K.</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Arvey</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Sudhamsu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Shrivastava&#x02010;Ranjan</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Hotard</surname>, <given-names>A. L.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Spiropoulou</surname>, <given-names>C. F.</given-names>
</string-name> (<year>2017</year>). <article-title>GS&#x02010;5734 and its parent nucleoside analog inhibit Filo&#x02010;, Pneumo&#x02010;, and Paramyxoviruses</article-title>. <source xml:lang="en">Scientific Reports</source>, <volume>7</volume>, <fpage>43395</fpage>
<pub-id pub-id-type="doi">10.1038/srep43395</pub-id>
<pub-id pub-id-type="pmid">28262699</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0049"><mixed-citation publication-type="journal" id="tbed13734-cit-0049">
<string-name>
<surname>Loginova</surname>, <given-names>S. I.</given-names>
</string-name>, <string-name>
<surname>Borisevich</surname>, <given-names>S. V.</given-names>
</string-name>, <string-name>
<surname>Maksimov</surname>, <given-names>V. A.</given-names>
</string-name>, <string-name>
<surname>Bondarev</surname>, <given-names>V. P.</given-names>
</string-name>, <string-name>
<surname>Kotovskaia</surname>, <given-names>S. K.</given-names>
</string-name>, <string-name>
<surname>Rusinov</surname>, <given-names>V. L.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Chupakhin</surname>, <given-names>O. N.</given-names>
</string-name> (<year>2011</year>). <article-title>Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)</article-title>. <source xml:lang="en">Antibiotiki I Khimioterapiia</source>, <volume>56</volume>, <fpage>10</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="tbed13734-bib-0050"><mixed-citation publication-type="journal" id="tbed13734-cit-0050">
<string-name>
<surname>Luban</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Bossolt</surname>, <given-names>K. L.</given-names>
</string-name>, <string-name>
<surname>Franke</surname>, <given-names>E. K.</given-names>
</string-name>, <string-name>
<surname>Kalpana</surname>, <given-names>G. V.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Goff</surname>, <given-names>S. P.</given-names>
</string-name> (<year>1993</year>). <article-title>Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B</article-title>. <source xml:lang="en">Cell</source>, <volume>73</volume>, <fpage>1067</fpage>&#x02013;<lpage>1078</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(93)90637-6</pub-id>
<pub-id pub-id-type="pmid">8513493</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0051"><mixed-citation publication-type="journal" id="tbed13734-cit-0051">
<string-name>
<surname>Masui</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Nabeshima</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ajisaka</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Yamauchi</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Itoh</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Ishii</surname>, <given-names>K.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Hiromatsu</surname>, <given-names>K.</given-names>
</string-name> (<year>2017</year>). <article-title>Maoto, a traditional Japanese herbal medicine, inhibits uncoating of influenza virus</article-title>. <source xml:lang="en">Evidence&#x02010;Based Complementary and Alternative Medicine</source>, <volume>2017</volume>, <fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1155/2017/1062065</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0052"><mixed-citation publication-type="journal" id="tbed13734-cit-0052">
<string-name>
<surname>Matsuyama</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kawase</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Nao</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Shirato</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Ujike</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kamitani</surname>, <given-names>W.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Fukushi</surname>, <given-names>S.</given-names>
</string-name> (<year>2020</year>). <article-title>The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15</article-title>. <source xml:lang="en">BioRxiv</source>, Preprint. <pub-id pub-id-type="doi">10.1101/2020.03.11.987016</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0053"><mixed-citation publication-type="journal" id="tbed13734-cit-0053">
<string-name>
<surname>McNally</surname>, <given-names>M. M.</given-names>
</string-name>, <string-name>
<surname>Wahlin</surname>, <given-names>K. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Canto&#x02010;Soler</surname>, <given-names>M. V.</given-names>
</string-name> (<year>2010</year>). <article-title>Endogenous expression of ASLV viral proteins in specific pathogen free chicken embryos: Relevance for the developmental biology research field</article-title>. <source xml:lang="en">BMC Developmental Biology</source>, <volume>10</volume>, <fpage>106</fpage>
<pub-id pub-id-type="doi">10.1186/1471-213X-10-106</pub-id>
<pub-id pub-id-type="pmid">20955591</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0054"><mixed-citation publication-type="journal" id="tbed13734-cit-0054">
<string-name>
<surname>Monini</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Cafaro</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Srivastava</surname>, <given-names>I. K.</given-names>
</string-name>, <string-name>
<surname>Moretti</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>, <given-names>V. A.</given-names>
</string-name>, <string-name>
<surname>Andreini</surname>, <given-names>C.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Ensoli</surname>, <given-names>B.</given-names>
</string-name> (<year>2012</year>). <article-title>HIV&#x02010;1 tat promotes integrin&#x02010;mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti&#x02010;HIV antibodies</article-title>. <source xml:lang="en">PLoS One</source>, <volume>7</volume>, <elocation-id>e48781</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0048781</pub-id>
<pub-id pub-id-type="pmid">23152803</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0055"><mixed-citation publication-type="journal" id="tbed13734-cit-0055">
<string-name>
<surname>Nguyen</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Gao</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>R.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Wei</surname>, <given-names>G.</given-names>
</string-name> (<year>2020</year>). <article-title>Potentially highly potent drugs for 2019&#x02010;nCoV</article-title>. <source xml:lang="en">BioRxiv</source>, Preprint. <pub-id pub-id-type="doi">10.1101/2020.02.05.936013</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0056"><mixed-citation publication-type="journal" id="tbed13734-cit-0056">
<string-name>
<surname>Ou</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Lei</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Mi</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Ren</surname>, <given-names>L.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Qian</surname>, <given-names>Z.</given-names>
</string-name> (<year>2020</year>). <article-title>Characterization of spike glycoprotein of SARS&#x02010;CoV&#x02010;2 on virus entry and its immune cross&#x02010;reactivity with SARS&#x02010;CoV</article-title>. <source xml:lang="en">Nature Communications</source>, <volume>11</volume>, <fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0057"><mixed-citation publication-type="journal" id="tbed13734-cit-0057">
<string-name>
<surname>Peters</surname>, <given-names>H. L.</given-names>
</string-name>, <string-name>
<surname>Jochmans</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>de Wilde</surname>, <given-names>A. H.</given-names>
</string-name>, <string-name>
<surname>Posthuma</surname>, <given-names>C. C.</given-names>
</string-name>, <string-name>
<surname>Snijder</surname>, <given-names>E. J.</given-names>
</string-name>, <string-name>
<surname>Neyts</surname>, <given-names>J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Seley&#x02010;Radtke</surname>, <given-names>K. L.</given-names>
</string-name> (<year>2015</year>). <article-title>Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti&#x02010;coronavirus activity</article-title>. <source xml:lang="en">Bioorganic &#x00026; Medicinal Chemistry Letters</source>, <volume>25</volume>, <fpage>2923</fpage>&#x02013;<lpage>2926</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2015.05.039</pub-id>
<pub-id pub-id-type="pmid">26048809</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0058"><mixed-citation publication-type="journal" id="tbed13734-cit-0058">
<string-name>
<surname>Pfefferle</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Sch&#x000f6;pf</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>K&#x000f6;gl</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Friedel</surname>, <given-names>C. C.</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Carbajo&#x02010;Lozoya</surname>, <given-names>J.</given-names>
</string-name>, &#x02026; <string-name>
<surname>von Brunn</surname>, <given-names>A.</given-names>
</string-name> (<year>2011</year>). <article-title>The SARS&#x02010;coronavirus&#x02010;host interactome: Identification of cyclophilins as target for pan&#x02010;coronavirus inhibitors</article-title>. <source xml:lang="en">PLoS Path</source>, <volume>7</volume>, <elocation-id>e1002331</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1002331</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0059"><mixed-citation publication-type="journal" id="tbed13734-cit-0059">
<string-name>
<surname>Pruijssers</surname>, <given-names>A. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Denison</surname>, <given-names>M. R.</given-names>
</string-name> (<year>2019</year>). <article-title>Nucleoside analogues for the treatment of coronavirus infections</article-title>. <source xml:lang="en">Current Opinion in Virology</source>, <volume>35</volume>, <fpage>57</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2019.04.002</pub-id>
<pub-id pub-id-type="pmid">31125806</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0060"><mixed-citation publication-type="journal" id="tbed13734-cit-0060">
<string-name>
<surname>Qin</surname>, <given-names>C. F.</given-names>
</string-name>, <string-name>
<surname>Qin</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>S. P.</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Deng</surname>, <given-names>Y. Q.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Zhao</surname>, <given-names>H.</given-names>
</string-name> (<year>2005</year>). <article-title>Therapeutic effects of dengue 2 virus capsid protein and staphylococcal nuclease fusion protein on dengue&#x02010;infected cell cultures</article-title>. <source xml:lang="en">Archives of Virology</source>, <volume>150</volume>, <fpage>659</fpage>&#x02013;<lpage>669</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-004-0451-3</pub-id>
<pub-id pub-id-type="pmid">15592886</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0061"><mixed-citation publication-type="journal" id="tbed13734-cit-0061">
<string-name>
<surname>Qin</surname>, <given-names>Z.&#x02010;L.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Cao</surname>, <given-names>M.&#x02010;M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Qi</surname>, <given-names>Z.&#x02010;T.</given-names>
</string-name> (<year>2007</year>). <article-title>siRNAs targeting terminal sequences of the SARS&#x02010;associated coronavirus membrane gene inhibit M protein expression through degradation of M mRNA</article-title>. <source xml:lang="en">Journal of Virological Methods</source>, <volume>145</volume>, <fpage>146</fpage>&#x02013;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2007.05.017</pub-id>
<pub-id pub-id-type="pmid">17590445</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0062"><mixed-citation publication-type="journal" id="tbed13734-cit-0062">
<string-name>
<surname>Ratia</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Pegan</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Takayama</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Sleeman</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Coughlin</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Baliji</surname>, <given-names>S.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Mesecar</surname>, <given-names>A. D.</given-names>
</string-name> (<year>2008</year>). <article-title>A noncovalent class of papain&#x02010;like protease/deubiquitinase inhibitors blocks SARS virus replication</article-title>. <source xml:lang="en">Proceedings of the National Academy of Sciences</source>, <volume>105</volume>, <fpage>16119</fpage>&#x02013;<lpage>16124</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0805240105</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0063"><mixed-citation publication-type="journal" id="tbed13734-cit-0063">
<string-name>
<surname>Richardson</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Tucker</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Oechsle</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Phelan</surname>, <given-names>A.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Stebbing</surname>, <given-names>J.</given-names>
</string-name> (<year>2020</year>). <article-title>Baricitinib as potential treatment for 2019&#x02010;nCoV acute respiratory disease</article-title>. <source xml:lang="en">Lancet</source>, <volume>395</volume>, <elocation-id>e30</elocation-id>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30304-4</pub-id>
<pub-id pub-id-type="pmid">32032529</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0064"><mixed-citation publication-type="journal" id="tbed13734-cit-0064">
<string-name>
<surname>Rosa</surname>, <given-names>S. G. V.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Santos</surname>, <given-names>W. C.</given-names>
</string-name> (<year>2020</year>). <article-title>Clinical trials on drug repositioning for COVID&#x02010;19 treatment</article-title>. <source xml:lang="en">Revista Panamericana De Salud P&#x000fa;blica</source>, <volume>44</volume>
<pub-id pub-id-type="doi">10.26633/RPSP.2020.40</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0065"><mixed-citation publication-type="journal" id="tbed13734-cit-0065">
<string-name>
<surname>Saraswat</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Chaudhary</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Sehgal</surname>, <given-names>D.</given-names>
</string-name> (<year>2020</year>). <article-title>Hepatitis E virus cysteine protease has papain like properties validated by in silico modeling and cell&#x02010;free inhibition assays</article-title>. <source xml:lang="en">Frontiers in Cellular and Infection Microbiology</source>, <volume>9</volume>, <fpage>478</fpage>
<pub-id pub-id-type="doi">10.3389/fcimb.2019.00478</pub-id>
<pub-id pub-id-type="pmid">32039053</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0066"><mixed-citation publication-type="journal" id="tbed13734-cit-0066">
<string-name>
<surname>Schoeman</surname>, <given-names>D.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Fielding</surname>, <given-names>B. C.</given-names>
</string-name> (<year>2019</year>). <article-title>Coronavirus envelope protein: Current knowledge</article-title>. <source xml:lang="en">Virology Journal</source>, <volume>16</volume>, <fpage>69</fpage>
<pub-id pub-id-type="doi">10.1186/s12985-019-1182-0</pub-id>
<pub-id pub-id-type="pmid">31133031</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0067"><mixed-citation publication-type="journal" id="tbed13734-cit-0067">
<string-name>
<surname>Schornberg</surname>, <given-names>K. L.</given-names>
</string-name>, <string-name>
<surname>Shoemaker</surname>, <given-names>C. J.</given-names>
</string-name>, <string-name>
<surname>Dube</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Abshire</surname>, <given-names>M. Y.</given-names>
</string-name>, <string-name>
<surname>Delos</surname>, <given-names>S. E.</given-names>
</string-name>, <string-name>
<surname>Bouton</surname>, <given-names>A. H.</given-names>
</string-name>, &#x00026; <string-name>
<surname>White</surname>, <given-names>J. M.</given-names>
</string-name> (<year>2009</year>). <article-title>&#x003b1;5 &#x003b2;1&#x02010;Integrin controls ebolavirus entry by regulating endosomal cathepsins</article-title>. <source xml:lang="en">Proceedings of the National Academy of Sciences</source>, <volume>106</volume>, <fpage>8003</fpage>&#x02013;<lpage>8008</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0807578106</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0068"><mixed-citation publication-type="journal" id="tbed13734-cit-0068">
<string-name>
<surname>Seo</surname>, <given-names>H. W.</given-names>
</string-name>, <string-name>
<surname>Seo</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<surname>Cho</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Ko</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>Y. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Jung</surname>, <given-names>G.</given-names>
</string-name> (<year>2019</year>). <article-title>Cetylpyridinium chloride interaction with the hepatitis B virus core protein inhibits capsid assembly</article-title>. <source xml:lang="en">Virus Research</source>, <volume>263</volume>, <fpage>102</fpage>&#x02013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2019.01.004</pub-id>
<pub-id pub-id-type="pmid">30639191</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0069"><mixed-citation publication-type="journal" id="tbed13734-cit-0069">
<string-name>
<surname>Shah</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Modi</surname>, <given-names>P.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Sagar</surname>, <given-names>S. R.</given-names>
</string-name> (<year>2020</year>). <article-title>In silico studies on therapeutic agents for COVID&#x02010;19: Drug repurposing approach</article-title>. <source xml:lang="en">Life Sciences</source>, <volume>252</volume>, <fpage>117652</fpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2020.117652</pub-id>
<pub-id pub-id-type="pmid">32278693</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0070"><mixed-citation publication-type="journal" id="tbed13734-cit-0070">
<string-name>
<surname>Sheahan</surname>, <given-names>T. P.</given-names>
</string-name>, <string-name>
<surname>Sims</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Graham</surname>, <given-names>R. L.</given-names>
</string-name>, <string-name>
<surname>Pruijssers</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Agostini</surname>, <given-names>M. L.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Baric</surname>, <given-names>R. S.</given-names>
</string-name> (<year>2020</year>). <article-title>An orally bioavailable broad&#x02010;spectrum antiviral inhibits SARS&#x02010;CoV&#x02010;2 in human airway epithelial cell cultures and multiple coronaviruses in mice</article-title>. <source xml:lang="en">Science Translational Medicine</source>, <volume>12</volume>, <elocation-id>eabb5883</elocation-id>
<pub-id pub-id-type="doi">10.1126/scitranslmed.abb5883</pub-id>
<pub-id pub-id-type="pmid">32253226</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0071"><mixed-citation publication-type="journal" id="tbed13734-cit-0071">
<string-name>
<surname>Shum</surname>, <given-names>K. T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Tanner</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2008</year>). <article-title>Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase</article-title>. <source xml:lang="en">ChemBioChem</source>, <volume>9</volume>, <fpage>3037</fpage>&#x02013;<lpage>3045</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.200800491</pub-id>
<pub-id pub-id-type="pmid">19031435</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0072"><mixed-citation publication-type="journal" id="tbed13734-cit-0072">
<string-name>
<surname>Sigrist</surname>, <given-names>C. J.</given-names>
</string-name>, <string-name>
<surname>Bridge</surname>, <given-names>A.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Le Mercier</surname>, <given-names>P.</given-names>
</string-name> (<year>2020</year>). <article-title>A potential role for integrins in host cell entry by SARS&#x02010;CoV&#x02010;2</article-title>. <source xml:lang="en">Antiviral Research</source>, <volume>177</volume>, <fpage>104759</fpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104759</pub-id>
<pub-id pub-id-type="pmid">32130973</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0073"><mixed-citation publication-type="journal" id="tbed13734-cit-0073">
<string-name>
<surname>Smith</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Smith</surname>, <given-names>J. C.</given-names>
</string-name> (<year>2020</year>). <article-title>Repurposing therapeutics for covid&#x02010;19: Supercomputer&#x02010;based docking to the sars&#x02010;cov&#x02010;2 viral spike protein and viral spike protein&#x02010;human ace2 interface</article-title>. <source xml:lang="en">ChemRxiv</source>, Preprint. <pub-id pub-id-type="doi">10.26434/chemrxiv.11871402.v4</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0074"><mixed-citation publication-type="journal" id="tbed13734-cit-0074">
<string-name>
<surname>Stebbing</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Phelan</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Tucker</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Oechsle</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>, <given-names>D.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Richardson</surname>, <given-names>P.</given-names>
</string-name> (<year>2020</year>). <article-title>COVID&#x02010;19: Combining antiviral and anti&#x02010;inflammatory treatments</article-title>. <source xml:lang="en">The Lancet Infectious Diseases</source>, <volume>20</volume>, <fpage>400</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30132-8</pub-id>
<pub-id pub-id-type="pmid">32113509</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0075"><mixed-citation publication-type="journal" id="tbed13734-cit-0075">
<string-name>
<surname>Stower</surname>, <given-names>H.</given-names>
</string-name> (<year>2020</year>). <article-title>Lopinavir&#x02010;ritonavir in severe COVID&#x02010;19</article-title>. <source xml:lang="en">Nature Medicine</source>, <volume>1</volume>
<pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0076"><mixed-citation publication-type="book" id="tbed13734-cit-0076">
<string-name>
<surname>Talluri</surname>, <given-names>S.</given-names>
</string-name> (<year>2020</year>). <source xml:lang="en">Virtual Screening Based Prediction of Potential Drugs for COVID&#x02010;19</source>. Preprints, 2020020418. <pub-id pub-id-type="doi">10.20944/preprints202002.0418.v2</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0077"><mixed-citation publication-type="journal" id="tbed13734-cit-0077">
<string-name>
<surname>Tanner</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>, <given-names>B.&#x02010;J.</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Watt</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>, <given-names>J.&#x02010;Q.</given-names>
</string-name>, <string-name>
<surname>Wong</surname>, <given-names>K.&#x02010;L.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Huang</surname>, <given-names>J.&#x02010;D.</given-names>
</string-name> (<year>2005</year>). <article-title>The adamantane&#x02010;derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus</article-title>. <source xml:lang="en">Chemistry &#x00026; Biology</source>, <volume>12</volume>, <fpage>303</fpage>&#x02013;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2005.01.006</pub-id>
<pub-id pub-id-type="pmid">15797214</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0078"><mixed-citation publication-type="journal" id="tbed13734-cit-0078">
<string-name>
<surname>Taylor</surname>, <given-names>J. K.</given-names>
</string-name>, <string-name>
<surname>Coleman</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Postel</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Sisk</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Bernbaum</surname>, <given-names>J. G.</given-names>
</string-name>, <string-name>
<surname>Venkataraman</surname>, <given-names>T.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Frieman</surname>, <given-names>M. B.</given-names>
</string-name> (<year>2015</year>). <article-title>Severe acute respiratory syndrome coronavirus ORF7a inhibits bone marrow stromal antigen 2 virion tethering through a novel mechanism of glycosylation interference</article-title>. <source xml:lang="en">Journal of Virology</source>, <volume>89</volume>, <fpage>11820</fpage>&#x02013;<lpage>11833</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02274-15</pub-id>
<pub-id pub-id-type="pmid">26378163</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0079"><mixed-citation publication-type="journal" id="tbed13734-cit-0079">
<string-name>
<surname>Tchesnokov</surname>, <given-names>E. P.</given-names>
</string-name>, <string-name>
<surname>Feng</surname>, <given-names>J. Y.</given-names>
</string-name>, <string-name>
<surname>Porter</surname>, <given-names>D. P.</given-names>
</string-name>, &#x00026; <string-name>
<surname>G&#x000f6;tte</surname>, <given-names>M.</given-names>
</string-name> (<year>2019</year>). <article-title>Mechanism of inhibition of Ebola Virus RNA&#x02010;dependent RNA polymerase by remdesivir</article-title>. <source xml:lang="en">Viruses</source>, <volume>11</volume>, <fpage>326</fpage>&#x02013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.3390/v11040326</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0080"><mixed-citation publication-type="journal" id="tbed13734-cit-0080">
<string-name>
<surname>Thanh</surname>, <given-names>L. T.</given-names>
</string-name>, <string-name>
<surname>Andreadakis</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>G&#x000f3;mez</surname>, <given-names>R. R.</given-names>
</string-name>, <string-name>
<surname>Tollefsen</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Saville</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Mayhew</surname>, <given-names>S.</given-names>
</string-name> (<year>2020</year>). <article-title>The COVID&#x02010;19 vaccine development landscape</article-title>. <source xml:lang="en">Nature Reviews Drug Discovery</source>, <volume>19</volume>, <fpage>305</fpage>&#x02013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1038/d41573-020-00073-5</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0081"><mixed-citation publication-type="journal" id="tbed13734-cit-0081">
<string-name>
<surname>Touret</surname>, <given-names>F.</given-names>
</string-name>, &#x00026; <string-name>
<surname>de Lamballerie</surname>, <given-names>X.</given-names>
</string-name> (<year>2020</year>). <article-title>Of chloroquine and COVID&#x02010;19</article-title>. <source xml:lang="en">Antiviral Research</source>, <volume>177</volume>, <fpage>104762</fpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104762</pub-id>
<pub-id pub-id-type="pmid">32147496</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0082"><mixed-citation publication-type="journal" id="tbed13734-cit-0082">
<string-name>
<surname>Tugizov</surname>, <given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Berline</surname>, <given-names>J. W.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Palefsky</surname>, <given-names>J. M.</given-names>
</string-name> (<year>2003</year>). <article-title>Epstein&#x02010;Barr virus infection of polarized tongue and nasopharyngeal epithelial cells</article-title>. <source xml:lang="en">Nature Medicine</source>, <volume>9</volume>, <fpage>307</fpage>&#x02013;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1038/nm830</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0083"><mixed-citation publication-type="journal" id="tbed13734-cit-0083">
<string-name>
<surname>Van Damme</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Goff</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Katsura</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Jorgenson</surname>, <given-names>R. L.</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>, <given-names>M. C.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Guatelli</surname>, <given-names>J.</given-names>
</string-name> (<year>2008</year>). <article-title>The interferon&#x02010;induced protein BST&#x02010;2 restricts HIV&#x02010;1 release and is downregulated from the cell surface by the viral Vpu protein</article-title>. <source xml:lang="en">Cell Host &#x00026; Microbe</source>, <volume>3</volume>, <fpage>245</fpage>&#x02013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2008.03.001</pub-id>
<pub-id pub-id-type="pmid">18342597</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0084"><mixed-citation publication-type="journal" id="tbed13734-cit-0084">
<string-name>
<surname>Vela</surname>, <given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Bowick</surname>, <given-names>G. C.</given-names>
</string-name>, <string-name>
<surname>Herzog</surname>, <given-names>N. K.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Aronson</surname>, <given-names>J. F.</given-names>
</string-name> (<year>2008</year>). <article-title>Genistein treatment of cells inhibits arenavirus infection</article-title>. <source xml:lang="en">Antiviral Research</source>, <volume>77</volume>, <fpage>153</fpage>&#x02013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2007.09.005</pub-id>
<pub-id pub-id-type="pmid">17961732</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0085"><mixed-citation publication-type="journal" id="tbed13734-cit-0085">
<string-name>
<surname>Walls</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Park</surname>, <given-names>Y. J.</given-names>
</string-name>, <string-name>
<surname>Tortorici</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Wall</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>McGuire</surname>, <given-names>A. T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Veesler</surname>, <given-names>D.</given-names>
</string-name> (<year>2020</year>). <article-title>Structure, function, and antigenicity of the SARS&#x02010;CoV&#x02010;2 spike glycoprotein</article-title>. <source xml:lang="en">Cell</source>, <volume>181</volume>, <fpage>281</fpage>&#x02013;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id>
<pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0086"><mixed-citation publication-type="journal" id="tbed13734-cit-0086">
<string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name> (<year>2020</year>). <article-title>Fast identification of possible drug treatment of coronavirus disease&#x02010;19 (COVID&#x02010;19) through computational drug repurposing study</article-title>. <source xml:lang="en">ChemRxiv</source>, Preprint. <pub-id pub-id-type="doi">10.26434/chemrxiv.11875446.v1</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0087"><mixed-citation publication-type="journal" id="tbed13734-cit-0087">
<string-name>
<surname>Wang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Cao</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>M.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Xiao</surname>, <given-names>G.</given-names>
</string-name> (<year>2020</year>). <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (SARS&#x02010;COV&#x02010;2) in vitro</article-title>. <source xml:lang="en">Cell Research</source>, <volume>30</volume>, <fpage>269</fpage>&#x02013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id>
<pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0088"><mixed-citation publication-type="journal" id="tbed13734-cit-0088">
<string-name>
<surname>Watashi</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Ishii</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Hijikata</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Murata</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Miyanari</surname>, <given-names>Y.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Shimotohno</surname>, <given-names>K.</given-names>
</string-name> (<year>2005</year>). <article-title>Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase</article-title>. <source xml:lang="en">Molecular Cell</source>, <volume>19</volume>, <fpage>111</fpage>&#x02013;<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2005.05.014</pub-id>
<pub-id pub-id-type="pmid">15989969</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0089"><mixed-citation publication-type="journal" id="tbed13734-cit-0089">
<string-name>
<surname>Wilson</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Mckinlay</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Gage</surname>, <given-names>P.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Ewart</surname>, <given-names>G.</given-names>
</string-name> (<year>2004</year>). <article-title>SARS coronavirus E protein forms cation&#x02010;selective ion channels</article-title>. <source xml:lang="en">Virology</source>, <volume>330</volume>, <fpage>322</fpage>&#x02013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2004.09.033</pub-id>
<pub-id pub-id-type="pmid">15527857</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0090"><mixed-citation publication-type="book" id="tbed13734-cit-0090">
<collab collab-type="authors">World Health Organization</collab>
(<year>2003</year>). <source xml:lang="en">Severe Acute Respiratory Syndrome (SARS) in Taiwan, China</source>. Retrieved from <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/2003_12_17/en/">https://www.who.int/csr/don/2003_12_17/en/</ext-link>
</mixed-citation></ref><ref id="tbed13734-bib-0091"><mixed-citation publication-type="book" id="tbed13734-cit-0091">
<collab collab-type="authors">World Health Organization</collab>
(<year>2013</year>). <source xml:lang="en">Novel Coronavirus Infection&#x02010;Update</source>. Retrieved from <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/2012_11_30/en/">https://www.who.int/csr/don/2012_11_30/en/</ext-link>
</mixed-citation></ref><ref id="tbed13734-bib-0092"><mixed-citation publication-type="journal" id="tbed13734-cit-0092">
<string-name>
<surname>Wu</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Seshaiah</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Natsoulis</surname>, <given-names>G.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Kappes</surname>, <given-names>J. C.</given-names>
</string-name> (<year>1995</year>). <article-title>Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx</article-title>. <source xml:lang="en">Journal of Virology</source>, <volume>69</volume>, <fpage>3389</fpage>&#x02013;<lpage>3398</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.69.6.3389-3398.1995</pub-id>
<pub-id pub-id-type="pmid">7745685</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0093"><mixed-citation publication-type="journal" id="tbed13734-cit-0093">
<string-name>
<surname>Xia</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Lan</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Feng</surname>, <given-names>S.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Liu</surname>, <given-names>S.</given-names>
</string-name> (<year>2020</year>). <article-title>Inhibition of SARS&#x02010;CoV&#x02010;2 infection (previously 2019&#x02010;nCoVSARS&#x02010;COV&#x02010;2) by a highly potent pan&#x02010;coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title>. <source xml:lang="en">Cell Research</source>, <volume>30</volume>, <fpage>343</fpage>&#x02013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0305-x</pub-id>
<pub-id pub-id-type="pmid">32231345</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0094"><mixed-citation publication-type="journal" id="tbed13734-cit-0094">
<string-name>
<surname>Xu</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Peng</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Shi</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Mu</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>X.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Zhu</surname>, <given-names>W.</given-names>
</string-name> (<year>2020</year>). <article-title>Nelfinavir was predicted to be a potential inhibitor of 2019&#x02010;nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation</article-title>. <source xml:lang="en">BioRxiv</source>, Preprint. <pub-id pub-id-type="doi">10.1101/2020.01.27.921627</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0095"><mixed-citation publication-type="journal" id="tbed13734-cit-0095">
<string-name>
<surname>Yamauchi</surname>, <given-names>Y.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Greber</surname>, <given-names>U. F.</given-names>
</string-name> (<year>2016</year>). <article-title>Principles of virus uncoating: Cues and the snooker ball</article-title>. <source xml:lang="en">Traffic</source>, <volume>17</volume>, <fpage>569</fpage>&#x02013;<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1111/tra.12387</pub-id>
<pub-id pub-id-type="pmid">26875443</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0096"><mixed-citation publication-type="journal" id="tbed13734-cit-0096">
<string-name>
<surname>Yang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Bai</surname>, <given-names>T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Hou</surname>, <given-names>X.</given-names>
</string-name> (<year>2020</year>). <article-title>Discovery of potential drugs for COVID&#x02010;19 based on the connectivity map</article-title>. <source xml:lang="en">Research Square</source>. <pub-id pub-id-type="doi">10.21203/rs.2.24684/v1</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0097"><mixed-citation publication-type="journal" id="tbed13734-cit-0097">
<string-name>
<surname>Yoon</surname>, <given-names>C. S.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>K. D.</given-names>
</string-name>, <string-name>
<surname>Park</surname>, <given-names>S. N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Cheong</surname>, <given-names>S. W.</given-names>
</string-name> (<year>2001</year>). <article-title>&#x003b1;6 integrin is the main receptor of human papillomavirus type 16 VLP</article-title>. <source xml:lang="en">Biochemical and Biophysical Research Communications</source>, <volume>283</volume>, <fpage>668</fpage>&#x02013;<lpage>673</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.2001.4838</pub-id>
<pub-id pub-id-type="pmid">11341777</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0098"><mixed-citation publication-type="journal" id="tbed13734-cit-0098">
<string-name>
<surname>Yu</surname>, <given-names>M. S.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Chin</surname>, <given-names>Y. W.</given-names>
</string-name>, <string-name>
<surname>Jee</surname>, <given-names>J. G.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Jeong</surname>, <given-names>Y. J.</given-names>
</string-name> (<year>2012</year>). <article-title>Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13</article-title>. <source xml:lang="en">Bioorganic &#x00026; Medicinal Chemistry Letters</source>, <volume>22</volume>, <fpage>4049</fpage>&#x02013;<lpage>4054</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2012.04.081</pub-id>
<pub-id pub-id-type="pmid">22578462</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0099"><mixed-citation publication-type="journal" id="tbed13734-cit-0099">
<string-name>
<surname>Zhai</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Ding</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Long</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zhong</surname>, <given-names>Y.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Li</surname>, <given-names>Y.</given-names>
</string-name> (<year>2020</year>). <article-title>The epidemiology, diagnosis and treatment of COVID&#x02010;19</article-title>. <source xml:lang="en">International Journal of Antimicrobial Agents</source>, <volume>55</volume>, <fpage>105955</fpage>
<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105955</pub-id>
<pub-id pub-id-type="pmid">32234468</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0100"><mixed-citation publication-type="journal" id="tbed13734-cit-0100">
<string-name>
<surname>Zhang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zou</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Pan</surname>, <given-names>T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Zhang</surname>, <given-names>H.</given-names>
</string-name> (<year>2020</year>). <article-title>Teicoplanin potently blocks the cell entry of 2019&#x02010;nCoV</article-title>. <source xml:lang="en">BioRxiv</source>, Preprint. <pub-id pub-id-type="doi">10.1101/2020.02.05.935387</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0101"><mixed-citation publication-type="journal" id="tbed13734-cit-0101">
<string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Kusov</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Nian</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Hilgenfeld</surname>, <given-names>R.</given-names>
</string-name> (<year>2020</year>). <article-title>&#x003b1;&#x02010;Ketoamides as broad&#x02010;spectrum inhibitors of coronavirus and enterovirus replication: Structure&#x02010;based design, synthesis, and activity assessment</article-title>. <source xml:lang="en">Journal of Medicinal Chemistry</source>, <volume>63</volume>, <fpage>4562</fpage>&#x02013;<lpage>4578</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01828</pub-id>
<pub-id pub-id-type="pmid">32045235</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0102"><mixed-citation publication-type="journal" id="tbed13734-cit-0102">
<string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Liu</surname>, <given-names>Y.</given-names>
</string-name> (<year>2020</year>). <article-title>Potential interventions for novel coronavirus in China: A systemic review</article-title>. <source xml:lang="en">Journal of Medical Virology</source>, <pub-id pub-id-type="doi">10.1002/jmv.25707</pub-id>
</mixed-citation></ref><ref id="tbed13734-bib-0103"><mixed-citation publication-type="journal" id="tbed13734-cit-0103">
<string-name>
<surname>Zhou</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>K.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Chen</surname>, <given-names>P. Y.</given-names>
</string-name> (<year>2008</year>). <article-title>Establishment and identification of classical swine fever virus (CSFV) capsid targeted nuclease expression system</article-title>. <source xml:lang="en">Chinese Journal of Virology</source>, <volume>24</volume>, <fpage>451</fpage>&#x02013;<lpage>455</lpage>.<pub-id pub-id-type="pmid">19226954</pub-id></mixed-citation></ref><ref id="tbed13734-bib-0104"><mixed-citation publication-type="journal" id="tbed13734-cit-0104">
<string-name>
<surname>Zhou</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>X.&#x02010;L.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>X.&#x02010;G.</given-names>
</string-name>, <string-name>
<surname>Hu</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>W.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Shi</surname>, <given-names>Z.&#x02010;L.</given-names>
</string-name> (<year>2020</year>). <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source xml:lang="en">Nature</source>, <volume>579</volume>, <fpage>270</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>
<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref></ref-list></back></article>